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ABSTRACT
These updated guidelines on the management of
variceal haemorrhage have been commissioned by the
Clinical Services and Standards Committee (CSSC) of the
British Society of Gastroenterology (BSG) under the
auspices of the liver section of the BSG. The original
guidelines which this document supersedes were written
in 2000 and have undergone extensive revision by 13
members of the Guidelines Development Group (GDG).
The GDG comprises elected members of the BSG liver
section, representation from British Association for the
Study of the Liver (BASL) and Liver QuEST, a nursing
representative and a patient representative. The quality
of evidence and grading of recommendations was
appraised using the AGREE II tool.
The nature of variceal haemorrhage in cirrhotic
patients with its complex range of complications makes
rigid guidelines inappropriate. These guidelines deal
speciﬁcally with the management of varices in patients
with cirrhosis under the following subheadings:
(1) primary prophylaxis; (2) acute variceal haemorrhage;
(3) secondary prophylaxis of variceal haemorrhage; and
(4) gastric varices. They are not designed to deal with
(1) the management of the underlying liver disease;
(2) the management of variceal haemorrhage in children;
or (3) variceal haemorrhage from other aetiological
conditions.
Summary of all recommendations
Recommendations: primary prophylaxis of variceal
haemorrhage in cirrhosis (Figure 2)
1. What is the best method for primary prophylaxis?
1.1. We recommend non-cardioselective β
blockers (NSBB) or variceal band ligation
(VBL). We suggest pharmacological treat-
ment with propranolol as ﬁrst line. VBL is
offered if there are contraindications to
NSBB. The choice of VBL or NSBB should
also take into account patient choice (level
1a, grade A).
1.2. We suggest carvedilol or nadolol as alterna-
tives to propranolol (level 1b, grade A).
1.3. Dose:
1.3.1. Propranolol: 40 mg twice daily. Dose
titrated to maximum tolerated or once
heart rate (HR) of 50–55 bpm is
reached to a maximum dose of
320 mg (level 1a, grade A).
1.3.2. Nadolol: 40 mg daily dose. Dose
titrated to maximum tolerated or
once HR of 50–55 bpm is reached a
maximum dose of 240 mg (level 1a,
grade A).
1.3.3. Carvedilol: 6.25 mg once daily to
increase to maintenance of 12.5 mg
after a week if tolerated or once HR
of <50–55 bpm is reached (level 1a,
grade A).
1.3.4. It is suggested that NSBB are discon-
tinued at the time of spontaneous
bacterial peritonitis, renal impair-
ment and hypotension (level 2b,
grade B).
1.4. In cases of contraindications or intolerance
to NSBB, we recommend variceal band
ligation (level 1a, grade A).
2. Who should have surveillance for variceal
bleeding?
2.1. We recommend all patients with cirrhosis
should be endoscoped at the time of diag-
nosis (level 1a, grade A). There is no indica-
tion to repeat endoscopy in patients
receiving NSBB.
3. How often should cirrhotic patients be
endoscoped?
3.1. If at the time of ﬁrst endoscopy no varices
are seen, we suggest that patients
with cirrhosis should be endoscoped at
2–3-year intervals (level 2a, grade B).
3.2. If grade I varices are diagnosed, we suggest
that patients should be endoscoped at yearly
intervals (level 2a, grade B).
3.3. If there is clear evidence of disease progres-
sion we suggest that the intervals can be
modiﬁed by the clinician. Endoscopy should
also be offered at time of decompensation
(level 2a, grade B).
4. Which patients with cirrhosis should have
primary prophylaxis?
4.1. If grade I varices and red signs or grade 2–
3 varices are diagnosed, we recommend
that patients have primary prophylaxis irre-
spective of the severity of the liver disease
(level 1a, grade A).
5. Treatments not recommended:
5.1. Proton pump inhibitors are not recom-
mended unless otherwise required for
peptic ulcer disease (level 1b, grade B).
5.2. Isosorbide mononitrate monotherapy is not
recommended as primary prophylaxis (level
1b, grade A). There is insufﬁcient evidence
to recommend isosorbide mononitrate in
combination with NSBB (level 1b, grade A).
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5.3. Shunt surgery or transjugular intrahepatic portosystemic
stent shunt (TIPSS) is not recommended as primary
prophylaxis (level 1a, grade A).
5.4. Sclerotherapy is not recommended as primary prophy-
laxis (level 1a, grade A).
6. Areas requiring further study:
6.1. Role of NSBB in patients without varices, with focus on
carvedilol.
6.2. Role of NSBB in patients with small varices, with focus
on carvedilol.
6.3. Comparison of carvedilol versus propranolol in primary
prophylaxis.
6.4. Identiﬁcation of, and trials assessing, new drugs for
primary prophylaxis such as statins.
7. Quality indicator:
7.1. Percentage of patients at diagnosis of cirrhosis who have
had an endoscopy to screen for varices (level 1a,
grade A).
Numerator; patients diagnosed with cirrhosis who have
had an endoscopy either before or after diagnosis within
6 months.
Denominator; patients newly diagnosed with cirrhosis.
7.2. Percentage of patients receiving primary prophylaxis
among those newly diagnosed with grade I varices and
red signs or grade 2–3 varices.
Numerator; patients who have grade 1 varices with red
signs or grade 2–3 varices receiving primary prophylaxis.
Denominator; patients diagnosed with cirrhosis who
have grade I varices with red signs or grade 2–3 varices.
Recommendations: control of active variceal haemorrhage in
cirrhosis (Figure 3)
1. Suggestions for resuscitation and initial management
1.1. Units offering an emergency acute upper gastrointestinal
bleeding service should have expertise in VBL, balloon
tamponade and management of gastric variceal bleeding
(level 5, grade D).
1.2. Transfuse patients with massive bleeding with blood, pla-
telets and clotting factors in line with local protocols for
managing massive bleeding (level 5, grade D).
1.3. Base decisions on blood transfusion on the full clinical
picture, recognising that overtransfusion may be as dam-
aging as undertransfusion. A restrictive transfusion policy
aiming for a haemoglobin of 70–80 g/L is suggested in
haemodynamically stable patients (level 1b, grade B).
1.4. Do not offer platelet transfusion to patients who are not
actively bleeding and are haemodynamically stable (level
5, grade D).
1.5. Offer platelet transfusion to patients who are actively
bleeding and have a platelet count of <50×109/L (level
5, grade D).
1.6. Offer fresh frozen plasma to patients who have either:
▸ a ﬁbrinogen level of <1 g/L (level 5, grade D), or
▸ a prothrombin time (international normalised ratio)
or activated partial thromboplastin time >1.5 times
normal (level 5, grade D).
1.7. Offer prothrombin complex concentrate to patients who
are taking warfarin and actively bleeding (level 5, grade D).
1.8. Treat patients who are taking warfarin and whose upper
gastrointestinal bleeding has stopped in line with local
warfarin protocols (level 5, grade D).
1.9. There is insufﬁcient evidence for the use of recombinant
factor VIIa in acute variceal haemorrhage (level 1b,
grade B).
2. Suggestions for timing of upper gastrointestinal endoscopy:
2.1. Offer endoscopy to unstable patients with severe acute
upper gastrointestinal bleeding immediately after resusci-
tation (level 5, grade A).
2.2. Offer endoscopy within 24 h of admission to all other
patients with upper gastrointestinal bleeding (level 2b,
grade A).
2.3. Units seeing more than 330 cases a year should offer
daily endoscopy lists. Units seeing fewer than 330 cases
a year should arrange their service according to local cir-
cumstances (level 5, grade D).
3. Control of bleeding:
3.1. Antibiotics are recommended for all patients with sus-
pected or conﬁrmed variceal bleeding (level 1a,
grade A).
3.2. In all patients, vasoconstrictors such as terlipressin or
somatostatin are recommended and should be started as
soon variceal bleeding is suspected and continued until
haemostasis is achieved or for up to 5 days. Octreotide
(unlicensed) is suggested if terlipressin or somatostatin
are unavailable (level 1a, grade A).
3.3. Variceal band ligation is recommended as the preferred
endoscopic method (level 1a, grade A).
3.4. After satisfactory haemostasis with the methods above,
and depending on local resources, early covered TIPSS
(<72 h after index variceal bleed) can be considered in
selected patients with Child’s B cirrhosis and active
bleeding or Child’s C cirrhosis with Child’s score <14
(level 1b, grade B).
3.5. Proton pump inhibitors are not recommended unless
otherwise required for peptic ulcer disease (level 1b,
grade B).
4. Failure to control active bleeding:
4.1. If bleeding is difﬁcult to control, a Sengstaken–
Blakemore tube should be inserted until further
endoscopic treatment, TIPSS or surgery is performed
depending on local resources and expertise (level 1b,
grade B).
4.2. Specialist help should be sought at this time and transfer
to a specialist centre should be considered. Units that do
not offer a TIPSS service should identify a specialist
centre which offers a 24 h emergency TIPSS service and
have appropriate arrangements for safe transfer of
patients in place (level 2a, grade B).
5. Areas requiring further study:
5.1. The efﬁcacy of restrictive blood transfusion in variceal
haemorrhage.
5.2. The role of blood products in variceal haemorrhage.
5.3. The utility of early TIPSS (<72 h) in acute variceal
haemorrhage.
5.4. The role of removable oesophageal stents in acute vari-
ceal haemorrhage.
5.5. The role of haemostatic powders in acute variceal
haemorrhage.
5.6. The role of proton pump inhibitors in variceal
haemorrhage.
6. Quality indicators
6.1. Antibiotic administration in acute variceal bleeding
within 1 day either before or after the procedure
(level 1a, grade A).
Numerator; patients with an acute variceal bleed who
have received antibiotics within 1 day either before or
after the procedure.
Denominator; patients with an acute variceal bleed.
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6.2. Endoscopy performed within 24 h of presentation of an
acute variceal bleed (level 2b, grade A).
Numerator; patients with an acute variceal bleed who
have received endoscopy within 24 h of presentation.
Denominator; patients with an acute variceal bleed.
Recommendations: secondary prophylaxis of variceal haemor-
rhage in cirrhosis (ﬁgure 3)
1. Should VBL be used in combination with NSBB?
1.1. NSBB (propranolol or nadolol)+VBL combination
therapy are recommended as secondary prophylaxis
(level 1a, grade A).
1.2. NSBB or VBL monotherapy are suggested as alternative
options taking into account patient preference and clin-
ical judgement (level 1a, grade B).
1.3. Carvedilol is suggested as an alternative to propranolol
and nadolol (level 1b, grade B).
1.4. If NSBB alone are used, there is no need to undertake
further endoscopy unless clinically indicated (level 1a,
grade A).
1.5. We recommend that VBL alone is used to eradicate
varices if there are contraindications or intolerance to
combined use with NSBB (level 1a, grade A).
2. What is the optimal protocol for VBL?
2.1. It is suggested that varices are banded at 2–4-weekly
intervals until eradication (level 1b, grade B).
2.2. After successful eradication of the varices, patients
should be endoscoped at 3 months, then 6 monthly
thereafter. Any recurrent varices should be treated with
further VBL until eradication (level 1b, grade B).
2.3. Proton pump inhibitors are not recommended unless
otherwise required for peptic disease (level 1b, grade B).
3. When is TIPSS indicated?
3.1. We suggest that TIPSS is used for patients who rebleed
despite combined VBL and NSBB therapy (or when
monotherapy with VBL or NSBB is used owing to
intolerance or contraindications to combination therapy),
and in selected cases owing to patient choice. PTFE-
covered stents are recommended (level 1a, grade A).
3.2. Where TIPSS is not feasible in Child’s A and B patients,
we suggest shunt surgery can be used where local
expertise and resources allow (level 1b, grade B).
4. Areas requiring further study:
4.1. Combination of VBL and carvedilol (or other NSBB)
versus carvedilol as monotherapy.
4.2. Comparison of carvedilol with propranolol in secondary
prophylaxis.
4.3. Optimum time interval between VBL sessions.
4.4. Strategy of VBL or NSBB discontinuation after variceal
eradication during combination therapy with VBL
+NSBB.
4.5. Strategy of VBL add-on therapy to failure of NSBB
monotherapy.
4.6. Strategy of NSBB add-on therapy to failure of VBL
monotherapy.
4.7. Role of early TIPSS in secondary prophylaxis.
4.8. Role of statins in secondary prophylaxis.
5. Quality indicator:
5.1. Institution of secondary prophylaxis after acute variceal
bleeding (level 1a, grade A)
Numerator; patients with an acute variceal bleed who
have received either NSBB or banding or both within
4 weeks of the index bleed.
Denominator; patients with an acute variceal bleed.
Recommendations: management of active haemorrhage from
gastric varices (Figure 3)
1. What is the optimal management of bleeding gastro-
oesophageal varices?
1.1. Gastro-oesophageal varices (GOV)-1: treat as for
oesophageal varices (level 2b, grade B).
1.2. GOV-2 and isolated gastric varices (IGV):
1.2.1. We recommend initial endoscopic therapy with
cyanoacrylate injection (level 1a, grade A).
1.2.2. Thrombin may also be considered (level 4, grade C).
1.3. TIPSS can be considered, depending on local resources
and clinical judgement (level 3a, grade B).
2. If control of bleeding fails:
2.1. Balloon tamponade is suggested for GOV and IGV-1
until deﬁnitive treatment is undertaken (level 2b, grade B).
2.2. Salvage TIPSS is suggested as the ﬁrst-line deﬁnite treat-
ment, where feasible (level 3a, grade B).
2.3. Balloon-occluded retrograde transvenous obliteration
(B-RTO) or surgical shunting can be considered if TIPSS
is not possible (eg, portal vein thrombosis present) and
depending on local resources (level 3a, grade B).
3. What are the therapeutic options for prevention of rebleed-
ing from gastric varices?
3.1. We recommend that patients with GOV-1 are entered into
a VBL surveillance programme (level 2b, grade B).
3.2. We recommend endoscopic surveillance with cyano-
acrylate injection as needed for GOV-2 and IGV (level
2b, grade B). Note the optimum endoscopic follow-up
strategy remains unclear. Thrombin can also be consid-
ered (level 4, grade C).
3.3. NSBB can be considered in certain circumstances after
taking into account the patient’s preferences and clinical
judgement (level 1b, grade B).
3.4. We suggest TIPSS if patients rebleed despite cyanoacryl-
ate injection. TIPSS can also be considered in other
selected patients (eg, those with large or multiple gastric
varices) (level 1b, grade B).
3.5. Shunt surgery may be used in selected patients with
well-compensated cirrhosis and depending on local
resources (level 3c, grade B).
3.6. Splenectomy or splenic artery embolisation should be
considered in all patients where there is splenic vein
thrombosis or left-sided portal hypertension (level 4,
grade C).
4. Is there a role for primary prophylaxis of gastric variceal
bleeding?
4.1. NSBB (level 2a, grade B) can be considered in selected
high-risk patients with large GOV-2 after taking into
account the patient’s preferences and clinical judgement.
4.2. Cyanoacrylate injection is not recommended outside
clinical trials (level 2a, grade A).
5. Areas requiring further study:
5.1. Role of thrombin in gastric varices, comparing this with
tissue adhesives in both acute gastric variceal bleeding
and secondary prophylaxis.
5.2. Role of TIPSS in acute gastric variceal bleeding and sec-
ondary prophylaxis.
5.3. Role of haemostatic powders in controlling refractory
active gastric variceal bleeding.
5.4. Role of NSBB in the prevention of rebleeding from
gastric varices.
5.5. Role of B-RTO as monotherapy or in combination with
endoscopic injection of tissue adhesives in prevention of
bleeding from gastric varices.
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5.6. Role of endoscopic ultrasound-guided injection of tissue
adhesives or thrombin.
5.7. Primary prevention of gastric variceal bleeding with
tissues adhesives and NSBB.
INTRODUCTION
The guidelines refer closely to the Baveno V consensus state-
ment published in 20101 and the 2012 NICE Guidelines on
Acute Upper GI bleeding (CG141).2 These documents are
widely used and offer useful evidence-based guidance. However,
we feel that owing to signiﬁcant recent advances, further addi-
tions and reﬁnements to the published guidance, with particular
focus on resource implications, service development and the
patient pathway, are necessary. The previously mentioned docu-
ments1 2 do not cover all the recent advances—in particular, in
the ﬁeld of acute variceal bleeding and the role of transjugular
intrahepatic portosystemic stent shunt (TIPSS). There have also
been developments and better insights into drug treatment for
prevention of varices and variceal bleeding—in particular, the
role of non-cardioselective β blockers (NSBB).
Guideline development
These guidelines were drafted after discussions within the liver
section of the British Society of Gastroenterology (BSG) and
acceptance of the proposal by the Clinical Services and
Standards Committee (CSSC). There followed division of sec-
tions to be researched by designated authors and an exhaustive
literature review. The Baveno V consensus and NICE guidelines
were closely followed and guideline quality was assessed using
the AGREE tool3 (section ‘Assessing the quality of guidelines:
the AGREE II instrument’).
A preliminary guideline document was drafted by the authors
following discussion and, where necessary, voting by members
of the Guidelines Development Group (GDG). The draft guide-
lines were submitted for review by CSSG, then BSG council
members. Finally, full peer review was undertaken by reviewers
selected by the editor of Gut.
Attempts were made to preserve the format of the original
guidelines, with additional sections relating to service develop-
ment, the patient pathway and pre-primary prophylaxis. The
section on the management of acute variceal bleeding has been
extensively rewritten to take into account recent important
developments in interventional radiology, drug treatment and
resuscitation.
Assessing the quality of guidelines: the AGREE II instrument
The AGREE II instrument is an accepted method for appraising
clinical guidelines.3 Six domains are listed:
Scope and purpose
The guidelines are intended for use by clinicians and other
healthcare professionals managing patients with cirrhosis and
gastro-oesophageal varices in light of recent guidance published
by NICE2 and the Baveno V Consensus.1 Important subsequent
developments are covered in depth due to the potential impact
on clinical practice. The guidelines are primarily aimed at man-
agement of adult patients
Guideline development group membership and stakeholder
involvement
Membership of the group includes gastroenterologists, hepatolo-
gists and interventional radiologists with nursing and patient
representation.
Rigour of development
The published literature was searched using Pubmed, Medline,
Web of Knowledge and the Cochrane database between October
2013 and February 2015. The GDG met through a series of tel-
econferences during that time. The guidelines rely considerably
on consensus statements published by the Baveno V Consensus
and NICE.1 2 The style of graded recommendations is deter-
mined by the level of supporting evidence (graded level 1 to 5)
as described by the Oxford Centre For Evidence Based
Medicine4 (table 1) and is as follows:
A: consistent level 1 studies;
B: consistent level 2 or 3 studies or extrapolations from level 1
studies;
C: level 4 studies or extrapolations from level 2 or 3 studies;
D: level 5 evidence or troublingly inconsistent or inconclusive
studies of any level.
Areas of disagreement about the recommendation grade were
subjected to discussion and, if necessary, voting by members of
the guidelines group. Where possible, the health beneﬁts, side
effects and risks of recommendations have been discussed. The
guidelines were subject to peer review after submission for con-
sideration of publication in Gut.
Clarity and presentation
Recommendations are intended to be speciﬁc to particular situa-
tions and patient groups; where necessary, different options are
listed. Key recommendations are linked to discussion threads on
a discussion forum hosted on the BSG website.
Applicability
Where necessary, we have discussed organisational changes that
may be needed in order to apply recommendations. We have
attempted to identify key criteria for monitoring and audit
purposes.
Editorial independence and conﬂict of interest
Guideline group members have declared any conﬂicts of
interest.
Scheduled review of guidelines
The proposed time for review of the guidelines is 5 years to
take into account new developments. To ensure that there is a
facility for feedback after publication, links to the BSG discus-
sion forums corresponding to the particular section of these
guidelines are included with this document. This facility to
provide new evidence is provided to all BSG members. In
accordance with the AGREE II tool the BSG forum will provide
feedback.
SERVICE DELIVERY AND DEVELOPMENT
Despite improvements in outcomes following variceal bleeding,
the need to optimise the management of acute variceal bleed-
ing is highlighted in recent publications and national reports.
In a national audit,5 variceal bleeding accounted for just over
10% of all admissions with acute GI bleeding in the UK, with
two-thirds having a previous history of variceal bleeding and
over 50% presenting during normal working hours. Endoscopy
within 24 h of presentation was achieved in only 66% of all
patients and in 70% of patients with documented cirrhosis.
Most procedures were performed in the endoscopy depart-
ment, with just 14% performed under general anaesthetic
despite high-risk stigmata and endoscopic therapy being
required in two-thirds of cases. Notably, antibiotics were
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administered in only 27% of patients before endoscopy, and
administration of vasoactive drugs before endoscopy was only
slightly higher at 44%. Furthermore, only four patients (<1%)
were referred for TIPSS, which may reﬂect the lack of access
to interventional radiology, and that the audit was conducted
before the trial of early TIPSS.6 The National Conﬁdential
Enquiry into Patient Outcome and Death (NCEPOD) report
‘Measuring the units’ assessed clinical management before
death of 594 patients with alcoholic liver disease over a
6-month period in the UK.7 Gastrointestinal bleeding was
noted in 35% of cases, with approximately 50% having vari-
ceal bleeding. Delays in endoscopy were noted in 10% of
cases, and several aspects of clinical and/or organisational care
were judged to be poor or unacceptable in 18% of patients
presenting with GI bleeding. There were deﬁciencies noted in
the out-of-hours rotas for GI bleeding, with 27% of hospitals
not having a dedicated-out-of hours GI bleeding service.
Studies from other countries have also reported deﬁciencies,
with delays in admission to hospital and administration of anti-
biotics. Two observational studies showed that access to
emergency endoscopy and use of prophylactic antibiotics and
vasoactive drugs was better in tertiary centres, although this
did not appear to affect survival.8 9
Acute variceal haemorrhage refractory to endoscopic and
pharmacological treatments, where TIPSS is usually indicated,
must be managed with appropriate resources. TIPSS is an estab-
lished interventional treatment for refractory or recurrent vari-
ceal haemorrhage. It remains a highly specialised procedure,
requiring adequate training and experience. Knowledge of the
relevant equipment, anatomy and how to deal with any compli-
cations is essential. It should therefore be performed in centres
with adequate personnel, multidisciplinary support and equip-
ment required to optimise management and minimise risks.10
Regional centres with easily accessible interventional radiology
services are generally best equipped to perform this procedure.
Setting up regional agreements and pathways to allow transfer of
appropriate patients to hospitals that undertake TIPSS proce-
dures is an important step. These pathways could also be used to
provide emergency endoscopic management if necessary due to
problems with out-of-hours endoscopic cover in smaller
Table 1 Levels of evidence
Level
Therapy/prevention, aetiology/
harm Prognosis Diagnosis DDX/symptom prevalence study
1a SR (with homogeneity*) of
randomised controlled trial (RCT)
SR (with homogeneity*) of inception
cohort studies; CDR† validated in
different populations
SR (with homogeneity*) of level 1
diagnostic studies; CDR† with 1b studies
from different clinical centres
SR (with homogeneity*) of
prospective cohort studies
1b Individual RCT (with narrow CI) Individual inception cohort study with
≥80% follow-up; CDR† validated in a
single population
Validating‡ cohort study with good§
reference standards; or CDR† tested
within one clinical centre
Prospective cohort study with good
follow-up¶
1c All or none** All or none case series Absolute SpPins and SnNouts†† All or none case series
2a SR (with homogeneity*) of cohort
studies
SR (with homogeneity*) of either
retrospective cohort studies or untreated
control groups in RCTs
SR (with homogeneity*) of level >2
diagnostic studies
SR (with homogeneity*) of 2b and
better studies
2b Individual cohort study (including
low-quality RCT; eg, <80%
follow-up)
Retrospective cohort study or follow-up
of untreated control patients in an RCT;
derivation of CDR† or validated on split
sample‡‡ only
Exploratory‡ cohort study with good§
reference standards; CDR† after
derivation, or validated only on split
sample‡‡ or databases
Retrospective cohort study, or poor
follow-up
2c ‘Outcomes’ research; ecological
studies
‘Outcomes’ research Ecological studies
3a SR (with homogeneity*) of case–
control studies
SR (with homogeneity*) of 3b and better
studies
SR (with homogeneity*) of 3b and
better studies
3b Individual case–control study Non-consecutive study; or without
consistently applied reference standards
Non-consecutive cohort study or
very limited population
4 Case series (and poor quality
cohort and case-control studies§§)
Case series (and poor quality prognostic
cohort studies¶¶)
Case–control study, poor or
non-independent reference standard
Case series or superseded reference
standards
5 Expert opinion without explicit
critical appraisal or based on
physiology, bench research or ‘first
principles’
Expert opinion without explicit critical
appraisal or based on physiology, bench
research or ‘first principles’
Expert opinion without explicit critical
appraisal or based on physiology, bench
research or ‘first principles’
Expert opinion without explicit
critical appraisal or based on
physiology, bench research or ‘first
principles’
*Homogeneity means a systematic review (SR) that is free of worrisome variations (heterogeneity) in the directions and degrees of results between individual studies. Not all SRs with
statistically significant heterogeneity need be worrisome, and not all worrisome heterogeneity need be statistically significant.
†CDR, Clinical Decision Rule (algorithms or scoring systems which lead to a prognostic estimation or a diagnostic category).
‡Validating studies test the quality of a specific diagnostic test based on prior evidence. An exploratory study collects information and trawls the data (eg, using a regression analysis) to
find which factors are ‘significant’.
§Good reference standards are independent of the test, and applied blindly or objectively to all patients. Poor reference standards are haphazardly applied, but still independent of the
test. Use of a non-independent reference standard (where the ‘test’ is included in the ‘reference’, or where the ‘testing’ affects the ‘reference’) implies a level 4 study.
¶Good follow-up in a differential diagnosis study is >80%, with adequate time for alternative diagnoses to emerge (eg, 1–6 months acute, 1–5 years chronic).
**Met when all patients died before the treatment became available but some now survive while receiving it; or when some patients died before the treatment became available but
none now die while receiving it.
††An ‘absolute SpPin’: a diagnostic finding whose Specificity is so high that a Positive result rules in the diagnosis. An ‘Absolute SnNout’: a diagnostic finding whose Sensitivity is so
high that a Negative result rules out the diagnosis.
‡‡Split-sample validation is achieved by collecting all the information in a single tranche, then artificially dividing this into ‘derivation’ and ‘validation’ samples.
§§Poor quality cohort study: one that failed to clearly define comparison groups and/or failed to measure exposures and outcomes in the same (preferably blinded) objective way in
both exposed and non-exposed individuals and/or failed to identify or appropriately control known confounders and/or failed to carry out a sufficiently long and complete follow-up of
patients. Poor quality case–control study: one that failed to clearly define comparison groups and/or failed to measure exposures and outcomes in the same (preferably blinded)
objective way in both cases and controls and/or failed to identify or appropriately control known confounders.
¶¶Poor quality prognostic cohort study: one in which sampling was biased in favour of patients who already had the target outcome, or the measurement of outcomes was
accomplished in <80% of study patients, or outcomes were determined in an unblinded non-objective way, or there was no correction for confounding factors.
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hospitals. This model referred to as “spoke and wheel” or
network model, is well established for other complex procedures
and helps to expedite and streamline the process. In the
NCEPOD report ‘Measuring the units’ just 15% of hospitals had
on-site access to TIPSS, while 72% had access to TIPSS in other
centres.7
There have been signiﬁcant efforts to address the need to
improve the upper GI bleeding (UGIB) service. A toolkit was
produced in collaboration with BSG; Association of Upper
Gastrointestinal Surgeons (AUGIS); Royal Colleges of
Physicians, Radiology and Nursing; and Academy of Medical
Royal Colleges.11 The key nine service standards recommended
by the document are detailed below:
1. There will be a nominated individual with the authority to
ensure implementation by the contracted provider.
2. Contracted providers will ensure the minimum service is
adequately resourced.
3. All patients with suspected UGIB should be properly
assessed and their risk scored on presentation.
4. All patients should be resuscitated before therapeutic
intervention.
5. All high-risk patients with UGIB should be endoscoped
within 24 h, preferably on a planned list in the ﬁrst instance.
6. For patients who require more urgent intervention either for
endoscopy, interventional radiology or surgery formal 24/7
arrangements must be available.
7. The necessary team, meeting an agreed competency level,
should be available throughout the complete patient pathway.
8. Each stage of the patient pathway should be carried out in
an area with ‘appropriate’ facilities, equipment and support
including staff experienced in the management of UGIB.
9. All hospitals must collect a minimum dataset in order to
measure service provision against auditable outcomes
(case-mix adjusted as appropriate).
NICE recommendations for endoscopy provision are detailed
in the section ‘Management of active variceal haemorrhage’
recommendations.2 The BSG has also produced a care bundle
for patients admitted with decompensated cirrhosis in light of
the NCEPOD report with a check list method which includes
gastrointestinal bleeding.12
Since the 2008 Darzi report, quality has become a priority
for the NHS.13 With these guidelines there is real opportunity
to introduce quality outcomes based on good clinical evidence.
Furthermore by incorporating them into the liver accreditation
scheme, Liver Quest, one can improve and assure quality in
liver services across the UK.14 Therefore a small number of
quality outcomes measures have been chosen and form part of
the key recommendations.15
DEFINITIONS
It is important to deﬁne the terms that should be used in the
context of a variceal bleed. These are the Baveno V consensus
deﬁnitions.1
Variceal haemorrhage
Variceal haemorrhage is deﬁned as bleeding from an oesopha-
geal or gastric varix at the time of endoscopy or the presence of
large oesophageal varices with blood in the stomach and no
other recognisable cause of bleeding. An episode of bleeding is
clinically signiﬁcant when there is a transfusion requirement for
2 units of blood or more within 24 h of the time zero, together
with a systolic blood pressure of <100 mm Hg or a postural
change of >20 mm Hg and/or pulse rate >100 bpm at time
zero (time zero is the time of admission to the ﬁrst hospital to
which the patient is taken).
Time frame of acute bleeding
The acute bleeding episode is represented by an interval of
120 h (5 days) from time zero. Evidence of any bleeding after
120 h is the ﬁrst rebleeding episode.
Failure to control active bleeding
Failure to control active bleeding is deﬁned as death or need to
change treatment deﬁned by one of the following criteria:16 17
1. Fresh haematemesis or nasogastric aspiration of ≥100 mL of
fresh blood ≥2 h after the start of a speciﬁc drug treatment
or therapeutic endoscopy.
2. Development of hypovolaemic shock.
3. 30 g/L drop in haemoglobin (9% drop of haematocrit)
within any 24 h period if no transfusion is given. This time
frame needs to be further validated.
Variceal rebleeding
Variceal rebleeding is deﬁned as the occurrence of a single
episode of clinically signiﬁcant rebleeding from portal hyperten-
sive sources from day 5. Clinically signiﬁcant rebleeding is
deﬁned as recurrent melaena or haematemesis in any of the fol-
lowing settings:
1. hospital admission;
2. blood transfusion;
3. 30 g/L drop in haemoglobin;
4. death within 6 weeks.
Early mortality
Death within 6 weeks of the initial episode of bleeding.
NATURAL HISTORY OF VARICES IN CIRRHOSIS
Development of varices
The rise in portal pressure is associated with the development
of collateral circulation, which allows the portal blood to be
diverted into the systemic circulation. These spontaneous shunts
occur (a) at the cardia through the intrinsic and extrinsic gastro-
oesophageal veins; (b) in the anal canal where the superior
haemorrhoidal vein belonging to the portal system anastomoses
with the middle and inferior haemorrhoidal veins which belong
to the caval system; (c) in the falciform ligament of the liver
through the para-umbilical veins, which are the remains of the
umbilical circulation of the fetus; (d) in the abdominal wall and
the retroperitoneal tissues, from the liver to the diaphragm,
veins in the lienorenal ligament, in the omentum and lumbar
veins; and (e) blood diversion from the diaphragm, gastric, pan-
creatic, splenic, and adrenal veins, which may drain into the left
renal vein.
Numerous lines of evidence suggest that varices develop and
enlarge with time. Christensen et al18 followed up a cohort of
532 patients with cirrhosis and showed that the cumulative inci-
dence of patients with varices increased from 12% to 90% over
12 years. In a study involving 80 patients followed up for
16 months, Cales and Pascal19 showed that 20% of patients
who did not have varices developed new varices and 42% of
patients with small varices showed deﬁnite enlargement. Czaja
et al20 also showed that the prevalence of varices increased from
8% to 13% over 5 years in a cohort of patients with chronic
active hepatitis even though they were treated with prednisol-
one. Merli et al,21 in a study of 213 patients with cirrhosis with
no or small varices, demonstrated that the annual progression of
varices was 12%. A recent database analysis by D’Amico et al22
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using a competing risk model showed that the cumulative inci-
dence of varices at 10 and 20 years was 44% and 53%, respect-
ively, suggesting an overestimation in previous studies not using
a competing risk model.
The main factors that appear to determine the development
of varices are continued hepatic injury, the degree of portosyste-
mic shunting, endoscopic appearances and portal pressure.
Evidence for the role of hepatic injury is derived from studies in
which varices were shown to regress with time. Baker et al23 fol-
lowed up a cohort of 115 patients with oesophageal varices and
showed that varices had disappeared in nine patients, regressed
in seven and remained unchanged in six. They concluded that
the disappearance and regression of varices might be related to
abstinence from alcohol. This observation was conﬁrmed in a
study by Dagradi24 who followed up a cohort of patients with
alcoholic cirrhosis over 3 years and showed a reduction in vari-
ceal size in 12 of the 15 patients with alcoholic cirrhosis who
stopped drinking and an enlargement in variceal size in 17
patients who continued to drink. On the other hand, Cales and
Pascal19 showed that regression of varices occurred in 16% of
patients with alcoholic cirrhosis who continued to imbibe
alcohol. This might be related to the development of large por-
tosystemic collaterals, which decompress the portal system and
reduce the risk of the development of large oesophageal varices.
The degree of portosystemic shunting can be quantiﬁed by
measuring the diameter of portal veins and collaterals, and can
be signiﬁcant in those with gastrorenal or splenorenal shunt-
ing.25 26 Others have shown that the presence of alcoholic cir-
rhosis, Child’s B or C cirrhosis and red whale signs on index
endoscopy predicted progression of varices.21 Groszmann
et al27 in a placebo-controlled randomised trial of timolol in
213 cirrhotic patients without varices showed that a baseline
hepatic venous pressure gradient (HVPG) of >10 mm Hg or a
≥10% increase in HVPG during follow-up were both predictive
of the development of varices.
Diagnosis of gastro-oesophageal varices
Until recently, endoscopy has been used exclusively to diagnose
varices. Non-invasive methods of screening for varices include
capsule endoscopy, transient elastography and use of laboratory
and radiological ﬁndings.
Endoscopy
There is universal acceptance that endoscopy is the ‘gold stand-
ard’ for diagnosing gastro-oesophageal varices. The main limita-
tions are intraobserver variability in the diagnosis of small or
grade I oesophageal varices (ﬁgure 1A–C). Recently, unsedated
nasal gastroscopy has been found to have similar accuracy to
conventional endoscopy and has the advantage of tolerability
and potential cost saving since it can be performed in the clinic
setting in some institutions.28 29 However, there are no con-
trolled studies and banding of varices is not possible.
Capsule endoscopy
Capsule endoscopy uses a 26 mm pill-shaped device which
transmits video footage which is stored and later analysed.
Patients are not sedated, but patient cooperation is essential.
In a large study by de Franchis et al,30 capsule endoscopy was
compared with standard gastroscopy. The primary end point of
90% or greater concordance was not achieved. Lapalus et al,31
in a prospective study of 120 patients, demonstrated similar
results with capsule endoscopy. Therefore, capsule endoscopy
cannot be considered an alternative to standard endoscopy,
although may have a role in patient who refuse gastroscopy.
Transient elastography
Transient elastography ((FibroScan, Echosens, Paris, France) uses
the principles of ultrasound to derive tissue stiffness by measur-
ing the speed of propagation of a low-frequency wave, which
then correlates with liver ﬁbrosis. Vizzutti et al32 in a study of
61 patients with hepatitis C showed a sensitivity for prediction
of oesophageal varices of 90% using a threshold 17.6 kPa.
However, speciﬁcity was poor at 43%. A study of 298 patients
found the optimal cut-off point for the prediction of oesopha-
geal varices was 21.5 kPa (sensitivity 76% and speciﬁcity
78%).33 In one uncontrolled study the use of transient elasto-
graphy was found to be as effective as HVPG at predicting
portal hypertension-related complications.34 Therefore, the role
of transient elastography in predicting varices is controversial
due to the lack of consistent results and controlled studies. This
modality may be more useful for predicting decompensation in
patients with cirrhosis.
Radiological and serum parameters.
A prospective study of 311 patients with chronic hepatitis C
showed that a platelet-to-spleen size ratio with a threshold of
909 had positive and negative predictive values of 100% and
94%, respectively.35 These good results have not been repro-
duced by others as demonstrated in a meta-analysis.36
Risk factors for ﬁrst variceal bleeding
The factors that predispose to, and precipitate, variceal haemor-
rhage are still not clear. The suggestion that oesophagitis may
precipitate variceal haemorrhage has been discarded.37
Presently, the most important factors that have been held
responsible include (i) pressure within the varix, (ii) variceal
size, (iii) tension on the variceal wall and (iv) severity of the
liver disease.
Portal pressure
In most cases, portal pressure reﬂects intravariceal pressure38
and a HVPG >10 mm Hg is necessary for the development of
oesophageal varices.27 There is no linear relationship between
the severity of portal hypertension and the risk of variceal
haemorrhage, although HVPG >12 mm Hg is an accepted
Figure 1 (A) Grade I oesophageal
varices. These collapse to inﬂation of
the oesophagus with air. (B) Grade II
oesophageal varices. These are varices
between grades 1 and 3. (C) Grade III
oesophageal varices. These are large
enough to occlude the lumen.
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threshold for variceal bleeding.39 40 However, the HVPG tends
to be higher in bleeders as well as in patients with larger varices.
In a prospective study comparing propranolol with placebo for
the prevention of ﬁrst variceal haemorrhage, Groszmann et al41
showed that bleeding from varices did not occur if the portal
pressure gradient (PPG) could be reduced to <12 mm Hg.
Others have shown that a 20% reduction in portal pressure pro-
tects against further bleeding.42 These haemodynamic goals
have been accepted as the aim of pharmacological treatment of
portal hypertension. It is important to appreciate that gastric
varices can bleed at pressures <12 mm Hg, and the inﬂuence of
wall tension of the varix plays a greater role in the risk of bleed-
ing.43 A greater pressure reduction may be necessary to protect
against bleeding. This is further discussed in the section ‘Gastric
varices’. At present, measurement of portal pressure in guiding
pharmacological treatments is limited to clinical trials in the UK.
Variceal size
Variceal size is best assessed endoscopically (ﬁgure 1A–C).
Published results are variable owing to the lack of a deﬁnition dis-
tinguishing between large and small varices. Small (grade I)
varices tend to be narrow and ﬂatten easily with air, whereas
larger (grade 2 and 3) varices are usually broader and ﬂatten with
difﬁculty, if at all. Numerous studies40 44 have shown that the
risk of variceal haemorrhage increases with the size of varices.45
Variceal wall and tension
Polio and Groszmann46 using an in vitro model showed that
rupture of varices was related to the tension on the variceal
wall. The tension depends on the radius of the varix. In this
model, increasing the size of the varix and decreasing the thick-
ness of the variceal wall caused variceal rupture. Recently, endo-
scopic ultrasound and manometry have been used to estimate
wall tension of varices.47
Endoscopic features such as ‘red spots’ and ‘whale’ markings
were ﬁrst described by Dagradi.24 They have been described as
being important in the prediction of variceal haemorrhage.
These features represent changes in variceal wall structure and
tension associated with the development of microtelangiectasias
and reduced wall thickness. In a retrospective study by the
Japanese Research Society for Portal Hypertension, Beppu
et al48 showed that 80% of patients who had blue varices or
cherry red spots bled from varices, suggesting that this was an
important predictor of variceal haemorrhage in cirrhosis.
Severity of liver disease and bleeding indices
Two independent groups prospectively assessed factors predict-
ing ﬁrst variceal haemorrhage in cirrhosis (table 2). The North
Italian Endoscopic Club (NIEC)49 reported their ﬁndings in
1988, followed in 1990 by data from the Japanese.50 Both these
studies showed that the risk of bleeding was based on three
factors: severity of liver disease as measured by Child class, vari-
ceal size and red wale markings. The NIEC study showed a
wide range for the risk of bleeding of 6–76%, depending on the
presence or absence of the different factors. Using the same vari-
ables the NIEC index was simpliﬁed by de Franchis et al51 and
shown to correlate with the original index. Further studies
showed that the HVPG and intravariceal pressure were also
independent predictors of ﬁrst variceal haemorrhage when ana-
lysed in conjunction with the NIEC index.52 53
In summary, the most important factors that determine the risk of
variceal haemorrhage are the severity of liver disease, size of varices,
and presence of red signs. Measurement of HVPG is a useful guide
for selection of patients for treatment and their response to
treatment, although the predictive value does not appear to
improve on the NIEC index and presence of red whale marking.54
Risk and mortality of ﬁrst variceal bleed
Data describing the overall risk of bleeding from varices must be
viewed with caution and have some pitfalls in interpretation.
The natural history of patients who have varices that are diag-
nosed as part of their baseline investiations is different from
that of patients who have complications of liver disease such as
ascites and encephalopathy. Most studies do not comment on
either the severity of liver disease or whether patients with alco-
holic cirrhosis are continuing to drink. Both these factors have a
signiﬁcant effect on the risk of variceal haemorrhage.
Most studies report bleeding from varices in about 20–50%
of patients with cirrhosis during the period of follow-up. Baker
et al23 reported variceal bleeding in 33 of 115 patients that they
followed up for a mean of 3.3 years, with a mortality of 48%
from the ﬁrst variceal haemorrhage. These data were conﬁrmed
by Christensen et al.18 About 70% of the episodes of bleeding
occur within 2 years of diagnosis. Recent studies demonstrate a
dramatic reduction in mortality following variceal bleeding of
20% 6-week mortality55 and 15% in-hospital mortality,5 with
contributions from improved endoscopic, pharmacological and
radiological therapies, notably TIPSS. Intensive care treatment
has also improved, with outcomes being particularly good for
those requiring minimal organ support.
Analysis of the non-active treatment arms in the primary
prophylaxis trials comparing propranolol with placebo show
results similar to those of the primary prophylaxis shunt trials,
with most episodes of bleeding occurring within the ﬁrst 2 years
of follow-up. In these studies the rate of ﬁrst variceal haemor-
rhage ranged from 22% to 61%.56–60 This large difference in
the rate of ﬁrst bleed relates almost certainly to the number of
patients with severe liver disease included in the study (Pascal,
Child C—46%, bleeding—61%; Italian Multicenter Project for
Propranolol in Prevention of Bleeding (IMPP), Child C—6%,
bleeding—32%; Conn, Child C—6%, bleeding—22%).
Mortality varied from 24% to 49% over 2 years (Pascal, mortal-
ity—49%; IMPP, mortality—24%; Conn, mortality—24%).
Primary prophylaxis
Since 30–50% of patients with portal hypertension will bleed
from varices and about 20% will die from the effects of the ﬁrst
Table 2 Scoring systems for quantifying the severity of cirrhosis
Severity of liver disease can be described using the Child–Pugh
score or MELD score.
The Child–Pugh score is the sum of severity scores for Child class,
variceal size and red wale markings the variables shown below.
Category 1 2 3
Encephalopathy 0 I/II III/IV
Ascites Absent Mild-moderate Severe
Bilirubin (μmol/L) <34 34–51 >51
Albumin (g/L) >35 28–35 <28
INR <1.3 1.3–1.5 >1.5
Child–Pugh class A represents a score of ≤6, class B a score of 7–9, and class C, ≥10.
The MELD score is a formula that includes three laboratory-based variables reflecting
the severity of liver disease. It was originally used to predict the short-term mortality
after placement of a transjugular intrahepatic portosystemic stent-shunt for variceal
bleeding. Subsequently, it has been used in selecting candidates for liver
transplantation.
MELD score: please use the online calculator https://www.esot.org/Elita/meldCalculator.
aspx.
INR, international normalised ratio.
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bleed, it seems rational to develop prophylactic regimens to
prevent the development of, and bleeding from, these varices.
However, most of the published trials do not have sufﬁcient
power to identify favourable treatment effects. Based on the
expected bleeding and death rates in the control group, the
minimum number of patients needed to detect a 50% reduction
in bleeding would be 270, and 850 patients in each arm to
detect the same reduction in mortality. A proposed algorithm
for surveillance and prophylaxis of varices is shown in ﬁgure 2.
At this time there is insufﬁcient evidence to support treating
patients without varices or ‘pre-primary prophylaxis’. A large
randomised placebo-controlled trial of timolol in patients
without varices and portal hypertension deﬁned as HVPG
>6 mm Hg did not show any effect on the development of
varices or variceal bleeding.27 The role of drug treatment in pre-
venting bleeding in patients with small varices is unclear. Three
randomised placebo-controlled trials have studied this. Cales
et al61 showed that propranolol in patients with small, or no,
varices resulted in greater development of varices. However,
patients without varices were included and there was signiﬁcant
loss of patients to follow-up. The second trial showed that
nadolol reduced variceal bleeding without survival beneﬁt and
increased adverse events.62 Sarin et al63 did not show any effect
with propranolol, despite a signiﬁcant effect on portal pressure.
Surgery
Portacaval shunts
Four trials of portacaval shunts have been published, which ran-
domised a total of 302 patients64–67 either to prophylactic shunt
surgery or to non-active treatment. A meta-analysis of these
studies showed a signiﬁcant beneﬁt in the reduction of variceal
bleeding (OR=0.31, 95% CI 0.17 to 0.56) but also a signiﬁ-
cantly greater risk of hepatic encephalopathy (OR=2, 95% CI
1.2 to 3.1) and mortality (OR=1.6, 95% CI 1.02 to 2.57) in
patients treated with shunt surgery.68 At this time, there is no
evidence for the use of TIPSS for primary prophylaxis.1
Devascularisation procedures
Inokuchi50 showed that there was a signiﬁcant reduction in vari-
ceal bleeding and in mortality in patients treated with a variety
of devascularisation procedures. There are, however, numerous
problems with the interpretation of this study because of the
use of different procedures in each of the 22 centres. These
results require conﬁrmation.
Pharmacological treatment
Non-cardioselective β blockers
The mainstay of the pharmacological approach to the primary
prophylaxis of variceal haemorrhage has been NSBB.
Propranolol which has been shown to reduce the PPG, reduce
azygos blood ﬂow, and also variceal pressure. It achieves this by
causing splanchnic vasoconstriction and reducing cardiac
output. There is no clear dose-related reduction in HVPG or
correlation of HPVG reduction with reduction in heart rate.69
Observational studies have shown that a 10–12% reduction in
HVPG after acute administration of propranolol was associated
with reduced bleeding and hepatic decompensation.54 70
However, HVPG monitoring is not routinely available in most
centres outside of larger institutions. A meta-analysis of nine
placebo-controlled randomised trials (964 patients) showed that
the pooled risk difference for bleeding was −11% (95% CI
−21% to −1%), and for death was −9% (95% CI −18% to
−1%) in favour of propranolol.71
Nadolol exerts similar effects on portal haemodynamics,
although the effect on blood pressure may not be as pro-
nounced. Two placebo-controlled trials58 59 have shown
reduced bleeding, although in one study this was only seen on
per protocol analysis.59 There was no effect on overall survival.
Carvedilol is a NSBB like propranolol, and a vasodilator due
to α1 receptor blockade. The latter reduces portocollateral
resistance, and by actions on hepatic stellate cells leads to a
reduction in intrahepatic resistance. Haemodynamic studies
demonstrate a greater reduction in portal pressure with
Figure 2 Algorithm for surveillance of varices and primary prophylaxis in cirrhosis.
*– If there is clear evidence of disease progression this interval can be modiﬁed by clinician. Endoscopy should also be offered at time of
decompensation.
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carvedilol than with propranolol, although blood pressure is
reduced.72 73 The optimum dose is 6.25–12.5 mg/day.74 Higher
doses are not more effective and are associated with more
adverse events—in particular, hypotension. Carvedilol at a dose
of 12.5 mg/day at current UK prices is considerably cheaper
than propranolol 40 mg twice a day and nadolol 80 mg/day
(monthly cost, £1.20, £5.62 and £5, respectively). Two RCTs of
carvedilol versus variceal band ligation (VBL) in primary
prophylaxis have been published.75 76 The ﬁrst study75 showed
signiﬁcantly reduced bleeding in the carvedilol arm (10% vs
23%, relative hazard 0.41; 95% CI 0.19 to 0.96), with no effect
on survival. The second trial by Shah et al76 did not show any
differences in bleeding or mortality. Compliance with VBL was
better in the latter trial, and unlike the ﬁrst trial, there were sig-
niﬁcantly more patients with viral hepatitis than alcoholic cir-
rhosis. A further study74 assessed the effect of carvedilol in
patients who were haemodynamic non-responders to propran-
olol, where haemodynamic response was deﬁned as HVPG
reduction to ≤12 mm Hg or by >20% of baseline after 4 weeks
of treatment. Patients who were haemodynamic non-responders
or intolerant to carvedilol were treated with VBL. Carvedilol
resulted in signiﬁcantly lower variceal bleeding compared with
VBL, and haemodynamic responders to carvedilol or propran-
olol had signiﬁcantly lower mortality than those treated with
VBL. It is worth noting that the study was not randomised.
There have been recent suggestions based on low-level evi-
dence that NSBB may result in a poorer outcome in patients
with cirrhosis and refractory ascites.77 The ‘window hypothesis’
for β blockers in cirrhosis has also recently been described, sug-
gesting that NSBB are helpful in the compensated and early
decompensated cirrhotic period, but may not be helpful in very
early cirrhosis, such as in a patient with no varices, and may be
harmful in patients with end-stage cirrhosis with refractory
ascites.78 However, recent large observational studies question
the last hypothesis, with improved survival seen in patients with
refractory ascites treated with NSBB,79 unless patients have an
episode of spontaneous bacterial peritonitis.80 Therefore, until
there are further prospective controlled studies, NSBB should be
continued in patients with refractory ascites. The clinician must
carefully monitor haemodynamic parameters such as blood pres-
sure, and discontinue NSBB in patients with hypotension and
renal impairment as can occur after an episode of spontaneous
bacterial peritonitis. Other potentially severe adverse events
with NSBB include symptomatic bradycardia, asthma and
cardiac failure. Less severe side effects such as fatigue, insomnia
and sexual dysfunction may also result.
Isosorbide mononitrate
Interest in the use of vasodilators such as isosorbide mononitrate
(ISMN) developed after the demonstration that it reduces portal
pressure as effectively as propranolol,81 but has subsequently
waned. A trial comparing ISMN with propranolol showed no
signiﬁcant difference between these agents.82 Another rando-
mised trial of ISMN versus placebo did show any difference in
the two arms.83 Therefore, ISMN is not recommended as
monotherapy in primary prophylaxis.
β Blocker and ISMN
The combination of nadolol and ISMN has been compared with
nadolol in a RCT. The combination therapy reduced the fre-
quency of bleeding signiﬁcantly but no signiﬁcant differences
were detected in mortality.84 However, Garcia-Pagan et al85 in a
double-blind RCTof propranolol plus ISMN versus propranolol
plus placebo failed to show any differences between the two
arms. Combination therapy is associated with more side effects.
Proton pump inhibitors
A placebo-controlled randomised trial reported reduced bleed-
ing and mortality with rabeprazole after eradication of varices.86
However, the study had a heterogeneous population with VBL
performed for both primary and secondary prophylaxis and
small numbers (n=43), limiting the validity of the conclusions.
Furthermore, there was no arm comparing proton pump inhibi-
tors with NSBB. The use of proton pump inhibitors in patients
with cirrhosis and ascites was associated with increased risk of
spontaneous bacterial peritonitis in a large retrospective study.87
This was not conﬁrmed in a larger prospective non-randomised
study.88 However, a recent prospective observational study has
shown proton pump use to be associated with increased mortal-
ity in cirrhosis.89 Proton pump inhibitors are also associated
with increased risk of Clostridium difﬁcile infection.90 There
remains continuing concern about proton pump inhibitors in
patients with cirrhosis, therefore caution should be used.
Endoscopic therapy
Variceal band ligation
VBL has been compared with NSBB in 19 trials in a recent
Cochrane meta-analysis of 1504 patients.91 Despite reduced
bleeding (RR=0.67, 95% CI 0.46 to 0.98) with VBL, there was
no difference in overall mortality and bleeding-related mortality.
The difference in bleeding was not seen when only trials with
low selection or attrition bias were included. Banding can have
serious complications. The risk of fatal banding-induced bleed-
ing was highlighted in a meta-analysis showing reduced fatal
adverse events with NSBB (OR=0.14, 95% 0.02 to 0.99).92
The optimal timing of banding intervals is discussed in the
section ‘Secondary prophylaxis of variceal haemorrhage’. A ran-
domised trial of 96 patients who underwent endoscopic surveil-
lance at 6 or 3 months after eradication of varices with VBL did
not demonstrate a difference in bleeding on mortality.93
However, the trial had a heterogeneous study group of patients
who underwent VBL both for primary (65%) and secondary
prevention (35%).
Sclerotherapy
Nineteen trials have compared endoscopic variceal sclerotherapy
with no treatment.68 Owing to the marked heterogeneity
between these studies a meta-analysis is clinically inappropri-
ate.68 Sclerotherapy does not offer any beneﬁt in combination
with NSBB or VBL compared with VBL or NSBB alone, and
increases iatrogenic complications such as strictures.94–96 At this
time sclerotherapy cannot be recommended for prophylaxis of
variceal haemorrhage in patients with cirrhosis.
Recommendations: primary prophylaxis of variceal haemor-
rhage in cirrhosis (ﬁgure 2)
1. What is the best method for primary prophylaxis?
1.1. We recommend NSBB or variceal band ligation (VBL).
We suggest pharmacological treatment with propranolol
as ﬁrst line. VBL is offered if there are contraindications
to NSBB. The choice of VBL or NSBB should also take
into account patient choice (level 1a, grade A).
1.2. We suggest carvedilol or nadolol as alternatives to pro-
pranolol (level 1b, grade A).
1.3. Dose:
1.3.1. Propranolol: 40 mg twice daily. Dose titrated to
maximum tolerated or once heart rate (HR) of
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50–55 bpm is reached to a maximum dose of
320 mg (level 1a, grade A).
1.3.2. Nadolol: 40 mg daily dose. Dose titrated to
maximum tolerated or once HR of 50–55 bpm is
reached a maximum dose of 240 mg (level 1a,
grade A).
1.3.3. Carvedilol: 6.25 mg once daily to increase to
maintenance of 12.5 mg after a week if tolerated
or once HR of <50–55 bpm is reached (level 1a,
grade A).
1.3.4. It is suggested that NSBB are discontinued at the
time of spontaneous bacterial peritonitis, renal
impairment and hypotension (level 2b, grade B).
1.4. In cases of contraindications or intolerance to NSBB, we
recommend variceal band ligation (level 1a, grade A).
2. Who should have surveillance for variceal bleeding?
2.1. We recommend all patients with cirrhosis should be
endoscoped at the time of diagnosis (level 1a, grade A).
There is no indication to repeat endoscopy in patients
receiving NSBB.
3. How often should cirrhotic patients be endoscoped?
3.1. If at the time of ﬁrst endoscopy no varices are seen, we
suggest that patients with cirrhosis should be endos-
coped at 2–3-year intervals (level 2a, grade B).
3.2. If grade I varices are diagnosed, we suggest that patients
should be endoscoped at yearly intervals (level 2a,
grade B).
3.3. If there is clear evidence of disease progression we
suggest that the intervals can be modiﬁed by a clinician.
Endoscopy should also be offered at time of decompen-
sation (level 2a, grade B).
4. Which patients with cirrhosis should have primary
prophylaxis?
4.1. If grade I varices and red signs or grade 2–3 varices are
diagnosed, we recommend that patients have primary
prophylaxis irrespective of the severity of the liver
disease (level 1a, grade A).
5. Treatments not recommended:
5.1. Proton pump inhibitors are not recommended unless
otherwise required for peptic ulcer disease (level 1b,
grade B).
5.2. Isosorbide mononitrate monotherapy is not recommended
as primary prophylaxis (level 1b, grade A). There is insufﬁ-
cient evidence to recommend isosorbide mononitrate in
combination with NSBB (level 1b, grade A).
5.3. Shunt surgery or TIPSS is not recommended as primary
prophylaxis (level 1a, grade A).
5.4. Sclerotherapy is not recommended as primary prophy-
laxis (level 1a, grade A).
6. Areas requiring further study:
6.1. Role of NSBB in patients without varices, with focus on
carvedilol.
6.2. Role of NSBB in patients with small varices, with focus
on carvedilol.
6.3. Comparison of carvedilol versus propranolol in primary
prophylaxis.
6.4. Identiﬁcation of, and trials assessing, new drugs for
primary prophylaxis such as statins.
7. Quality indicator:
7.1. Percentage of patients at diagnosis of cirrhosis who have
had an endoscopy to screen for varices (level 1a,
grade A).
Numerator; patients diagnosed with cirrhosis who have
had an endoscopy either before or after diagnosis within
6 months.
Denominator; patients newly diagnosed with cirrhosis.
7.2. Percentage of patients receiving primary prophylaxis
among those newly diagnosed with grade I varices and
red signs or grade 2–3 varices.
Numerator; patients who have grade 1 varices with red
signs or grade 2–3 varices receiving primary prophy-
laxis.
Denominator; patients diagnosed with cirrhosis who
have grade I varices with red signs or grade 2–3 varices.
MANAGEMENT OF ACTIVE VARICEAL HAEMORRHAGE
The average 6-week mortality of the ﬁrst episode of variceal
bleeding in most studies is reported to be up to 20%. There has
been considerable improvement in survival since the early 1980s
when the in-hospital mortality was 40–50%,97 compared with
15% from a recent UK audit.5 Such is the improvement in out-
comes, that a patient with Child’s A cirrhosis is very unlikely to
succumb to an index variceal bleed. Studies have shown the
Child–Pugh score, MELD score, and HVPG to be strong predic-
tors of outcomes.98–103 The MELD score has been shown to
outperform Child’s score in a recent study, with a score >19
associated with 20% 6 week mortality.103 Furthermore, the
MELD score has been shown to perform as well as the trad-
itional intensive care unit scores in predicting mortality in
patients admitted to intensive care in the UK.104 MELD >18,
active bleeding, transfusing >4 units of packed red blood cells
have been shown to be predictors of mortality and early
rebleeding.99 101 102 HVPG has also been shown to predict
outcome when measured at 2 weeks after a bleed,44 and a value
of ≥20 mm Hg when measured acutely within 48 h has been
shown to provide signiﬁcant prognostic information.100
However, this technique is not used routinely in the manage-
ment of patients around the world, and substitution of clinical
data in the latter study was shown to provide the same clinical
predictive value.100 These scoring systems are not purely aca-
demic; they allow the referring clinician to predict those
patients with a high chance of rebleeding to be transferred to a
specialist centre offering, for instance, TIPSS before the patient
rebleeds.
Nonetheless, probably the most important step in the man-
agement of acute variceal haemorrhage is the initial resuscitation
assessed according to standard ‘ABC’ practice, together with
protection of the airway to prevent aspiration. Although early
endoscopy allows for accurate diagnosis of the bleeding site and
decisions about management (ﬁgure 3), therapeutic intervention
in acute variceal bleeding can be initiated, safely in most cases,
before diagnostic endoscopy. As similar efﬁcacy is demonstrated
with pharmacological treatment as with sclerotherapy, the
former should be ﬁrst-line therapy.99 β Blockade should not be
started in the acute setting, and those already taking β blockers
as prophylaxis should probably stop taking them for 48–72 h in
order that the patient’s physiological response to blood loss can
be allowed to manifest.
General considerations
Patient evaluation
The majority of patients with a variceal bleed will be sufﬁciently
stable to enable a full history and examination to take place.
History of alcohol excess and or intravenous drug use should be
sought and may become particularly relevant if the patient has
withdrawal symptoms after admission. Comorbidity is important
when estimating risk and deciding on use of vasopressors. The
1690 Tripathi D, et al. Gut 2015;64:1680–1704. doi:10.1136/gutjnl-2015-309262
Guidelines
 o
n
 3 June 2019 by guest. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2015-309262 on 17 April 2015. Downloaded from 
following risk factors doubled mortality after an acute variceal
bleed in one US study: older age, comorbidities, male gender and
not undergoing a gastroscopy within 24 h.105
A full examination is helpful for the important negatives as
much as the positives. Baseline observations should include the
temperature, as infection is a serious complication with signiﬁ-
cant mortality. Confusion may be present because of encephal-
opathy, intoxication with alcohol or drugs or withdrawal from
alcohol or drugs. The patient should be on continuous BP and
pulse monitor and their haemodynamic status recorded.
An oxygen saturation monitor is helpful. Stigmata of chronic
liver disease and concurrent jaundice provide insight into the
current status of a patient’s liver, and also give warning of
potential further decompensation if signiﬁcant bleeding persists
(see scoring systems above). Pneumonia must be actively
excluded. Evidence of ascites requires a diagnostic tap to search
for infection.
Investigations including full blood count, coagulation
proﬁle, liver and renal function and blood group and save and
cross-match. Blood and urine should also be cultured. An ultra-
sound scan later in the admission is helpful to identify subclin-
ical ascites, ﬂow in portal vein and any obvious emergence of an
hepatocellular carcinoma (HCC).
Location of patient
A decision must be made as to where the patient is best managed.
Variceal bleeding is unpredictable, generally occurs in patients
with signiﬁcant liver disease and is associated with signiﬁcant mor-
tality. Hence, a high-dependency unit is usually the most appropri-
ate initial location, although a properly staffed ‘gastrointestinal
Figure 3 Algorithm for the
management of acute variceal
bleeding. TIPSS, transjugular
intrahepatic portosystemic stent shunt.
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bleeding bed’ may be appropriate. If a patient is vomiting blood,
or there is a perceived risk of a haemodynamically unstable patient
having blood in the stomach, then the patient must be intubated
before endoscopy, and return to an intensive care or high-
dependency unit will be necessary until extubation.
Volume resuscitation and blood products
Intravenous access (two 16–18G cannulae) should have been
secured on admission with a reported GI bleed. Further intra-
venous access may be necessary. In patients with poor venous
access, advanced liver disease, or renal failure associated with
their liver disease, central venous access may be helpful with
guiding ﬂuid infusions. However, the drawbacks include the risk
of the procedure and a potential source of infection. Therefore,
there is no absolute requirement for a central line, and no evi-
dence of unequivocal beneﬁt. Intravenous ﬂuid resuscitation
should be initiated with plasma expanders aiming to maintain a
systolic blood pressure of 100 mm Hg. Care with monitoring is
paramount in this group of patients.
Overtransfusion has been shown to have a deleterious effect
on outcome. In a recent single-centre RCT, a restrictive transfu-
sion policy of maintaining haemoglobin between 70 and 80 g/L
improved the control of variceal bleeding (11% vs 22%,
p=0.05), and lowered HVPG compared with a liberal transfu-
sion policy without effect on 45-day survival.106 However, it
should be noted that these results were from a single Spanish
centre, which was a tertiary unit for variceal bleeding, where all
patients underwent endoscopy within 6 h. Nonetheless, a
restrictive transfusion policy has been recommended for some
time1 and there is now good evidence to support not transfusing
a stable patient with a haemoglobin of ≥80 g/L. However, under-
resuscitation should also be avoided and while goal-oriented
ﬂuid replacement has generally not been useful in an intensive
therapy unit setting, a venous saturation >70% remains an easily
measurable target with some evidence to support it.107
Interpretation and management of clotting proﬁle is challen-
ging in liver disease, where there is usually a balanced deﬁciency
of both procoagulant and anticoagulant factors.108 The NICE
guidelines recommend activation of a hospital’s massive transfu-
sion policy when there is major haemorrhage, and platelet
support when the value is <50, and clotting factor support
when the international normalised ratio (INR) is >1.5 times
normal.2 There is no evidence for the use of ‘prophylactic’ clot-
ting or platelet support to reduce the risk of rebleeding. There
is insufﬁcient evidence to support the routine use of transexamic
acid, or recombinant factor VIIa.109
Pharmacological treatment
The two major classes of drugs that have been used in the
control of acute variceal bleeding are vasopressin or its analo-
gues (either alone or in combination with nitroglycerine) and
somatostatin or its analogues. Terlipressin is the only agent that
has been shown to reduce mortality in placebo-controlled trials.
However, in trials comparing terlipressin, somatostatin and
octreotide, no difference in efﬁcacy was identiﬁed in a system-
atic review110 and in a recent large RCT.111 Prophylactic anti-
biotics can result in a similar survival beneﬁt following acute
variceal bleeding.
Vasopressin
Vasopressin reduces portal blood ﬂow, portal systemic collateral
blood ﬂow and variceal pressure. It does, however, have signiﬁ-
cant systemic side effects such as an increase in peripheral resist-
ance, and reduction in cardiac output, heart rate and coronary
blood ﬂow. In comparison with no active treatment, the pooled
results of four randomised trials showed that it reduced failure
to control variceal bleeding (OR=0.22, 95% CI 0.12 to 0.43),
although survival was unaffected.68 Meta-analysis of ﬁve trials
comparing sclerotherapy with vasopressin has shown a signiﬁ-
cant effect on reduction in failure to control bleeding
(OR=0.51, 95% CI 0.27 to 0.97), with no effect on survival.68
Vasopressin with nitroglycerine
The addition of nitroglycerine enhances the effect of vasopres-
sin on portal pressure and reduces cardiovascular side effects.112
Meta-analysis of three randomised trials comparing vasopressin
alone with vasopressin and nitroglycerine showed that the com-
bination was associated with a signiﬁcant reduction in failure to
control bleeding (OR=0.39, 95% CI 0.22 to 0.72), although no
survival beneﬁt was shown.68
Terlipressin
Terlipressin is a synthetic analogue of vasopressin, which has an
immediate systemic vasoconstrictor action followed by portal
haemodynamic effects due to slow conversion to vasopressin. In
a Cochrane meta-analysis of seven placebo-controlled trials, ter-
lipressin was shown to reduce failure to control bleeding
(RR=0.66, 95% CI 0.55 to 0.93) and also to improve survival
(RR=0.66, 95% CI 0.49 to 0.88).113 In the same meta-analysis,
there was no difference between terlipressin versus vasopressin,
balloon tamponade or endoscopic therapy in failure to control
bleeding or survival.113 The role of terlipressin in combination
with VBL is explored in the section ‘Endoscopic therapy in
combination with pharmacological therapy’.
The recommended dose of terlipressin is 2 mg IV every 4 h,
although many units reduce the dose to 6 hourly as it may cause
peripheral vasoconstriction which manifests as painful hands
and feet. While 5 days of IV treatment has been advocated in
the Baveno V guidelines,1 this prolonged treatment has not
been shown to have a survival beneﬁt, and for pragmatic
reasons many units will stop treatment shortly after satisfactory
haemostasis. In a randomised trial terlipressin given for 24 h
after satisfactory haemostasis with VBL after oesophageal vari-
ceal bleeding was as effective as 72 h of treatment.114
In patients intolerant of terlipressin or in countries where ter-
lipressin is not available, alternatives should be considered.
Somatostatin and octreotide
Somatostatin causes selective splanchnic vasoconstriction and
reduces portal pressure and portal blood ﬂow.115 Octreotide is a
somatostatin analogue. The mechanism of action of these two
agents is not clear. Inhibition of glucagon increases vasodilatation
rather than a direct vasoconstrictive effect and post-prandial gut
hyperaemia is also reduced. The actions of octreotide on hepatic
and systemic hemodynamics are transient, making continuous
infusion necessary. Octreotide is given as a 50 μg bolus followed
by an infusion of 25–50 μg/h. Somatostatin is given as a 250 mg
intravenous bolus followed by an infusion of 250 mg/h.
Somatostatin and octreotide have been shown to be as
effective as terlipressin in acute variceal bleeding in a
meta-analysis.110 Seo et al111 in a large RCTof 780 patients com-
paring these three agents failed to show a difference in treatment
success (range 83.8–86.2%), rebleeding (range 3.4–4.4%) and
mortality (range 8–8.8%). A low systolic blood pressure at pres-
entation, high serum creatinine level, active bleeding in the emer-
gency endoscopy, gastric variceal bleeding and Child–Pugh grade
C were independent factors predicting 5-day treatment
failure.111
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Antibiotics
Antibiotics that provide Gram-negative cover are one of the inter-
ventions which positively inﬂuence survival in variceal haemor-
rhage as shown in a Cochrane meta-analysis of 12
placebo-controlled trials (RR=0.79, 95% CI 0.63 to 0.98).116
Antibiotics were also shown to reduce bacterial infections
(RR=0.43, 95% CI 0.19 to 0.97) and early rebleeding (RR=0.53,
95% CI 0.38 to 0.74).116 Therefore, short-term antibiotics should
be considered standard practice in all cirrhotic patients who have a
variceal bleed, irrespective of the presence of conﬁrmed infection.
Third-generation cephalosporins, such as ceftriaxone (1 g IV,
daily), have been shown to be more effective at reducing
Gram-negative sepsis than oral norﬂoxacin,117 but choice of anti-
biotics must be dictated by local resistance patterns and availability.
Proton pump inhibitors
One RCT compared a short course of proton pump inhibitors
with vasoconstrictor therapies after haemostasis in acute variceal
bleeding.118 Despite larger ulcers noted in the vasoconstrictor
arm, there were no differences in bleeding or survival. Nearly
50% of patients had ascites, which might have implications in
light of the reports of increased incidence of spontaneous bac-
terial peritonitis as mentioned earlier.
Endoscopic therapy
Endoscopy should take place within 24 h of admission and
earlier if there is excessive bleeding, based on low-level evi-
dence.105 While many guidelines and reviews suggest that
endoscopy should be carried out within 12 h the only study that
examined the inﬂuence of timing on outcome failed to demon-
strate any advantage of endoscopy before 12 h.119 The optimal
time is after sufﬁcient resuscitation, and pharmacological treat-
ment, with the endoscopy performed by a skilled endoscopy
team, in a suitably equipped theatre environment and with
airway protection. Airway protection is essential where risk of
aspiration is high, and affords the endoscopist time for thorough
evaluation, including complete clot aspiration and controlled
application of treatment, including tamponade if required. The
endoscopy team must comprise an experienced endoscopy
nurse acquainted with the equipment necessary for endoscopy
therapy of varices, and a skilled endoscopist, competent in using
banding devices and deployment of balloon tamponade.
Variceal band ligation
This technique is a modiﬁcation of that used for the elastic band
ligation of internal haemorrhoids. Its use in humans was ﬁrst
described in 1988.120 A meta-analysis of seven trials comparing
VBL with sclerotherapy in acute bleeding showed that VBL
reduced rebleeding from varices (OR=0.47, 95% CI 0.29 to
0.78), reduced mortality (OR=0.67, 95% CI 0.46 to 0.98) and
resulted in fewer oesophageal strictures (OR=0.10, 95% CI
0.03 to 0.29).121 The number of sessions required to obliterate
varices was lower with VBL (2.2 fewer sessions (95% CI 0.9
to 3.5)).
Sclerotherapy
Sclerotherapy has been replaced by VBL and should no longer
be offered as standard of care in acute variceal haemorrhage.
Other endoscopic measures
In an RCT, cyanoacrylate offered no beneﬁt over VBL, with the
additional risk of embolisation and trend towards increased
rebleeding with cyanoacrylate.122
Haemostatic powder (TC-325; Hemospray; Cook Medical,
USA) has been described in a small study of nine patients who
received endoscopic spray treatment for acute variceal bleeding.
The study reported no rebleeding within 24 h and no mortality
at 15 days.123
Endoscopic therapy in combination with pharmacological therapy
The role of combining vasoactive drugs with endoscopic
therapy (VBL or sclerotherapy) was reported in a meta-analysis
of eight trials.124 Combination therapy resulted in better initial
control of bleeding (RR=1.12, 95% CI 1.02 to 1.23), and
5-day haemostasis (RR=1.28, 95% CI 1.18 to 1.39), without
any difference in survival. Adverse events were similar in both
groups. Two RCTs have compared VBL with sclerotherapy in
combination with vasoactive agents in acute variceal bleed-
ing.125 126 Lo et al125 used vasopressin and found that VBL
resulted in better 72 h haemostasis (97% vs 76%, p=0.009),
with fewer complications (5% vs 29%, p=0.007). Villanueva
et al used somatostatin, and reported lower failure to control
acute bleeding with VBL (4% vs 15%, p=0.02), with fewer
serious complications (4% vs 13%, p=0.04). Overall survival
was similar in both trials.125 126
Balloon tamponade
Balloon tamponade is highly effective and controls acute bleed-
ing in up to 90% of patients although about 50% rebleed when
the balloon is deﬂated.127 128 It is, however, associated with
serious complications such as oesophageal ulceration and aspir-
ation pneumonia in up to 15–20% of patients. Despite this, it
may be a life-saving treatment in cases of massive uncontrolled
variceal haemorrhage pending other forms of treatment. An
appropriately placed Sengstaken–Blakemore tube allows for
resuscitation, safe transportation and either repeat endoscopy or
radiological shunting in a patient with a stable cardiovascular
system. The oesophageal balloon is rarely required, must never
be used on its own and should be used only if there is continu-
ing bleeding despite an adequately inﬂated gastric balloon cor-
rectly placed and with appropriate tension. Placement of the
tube endoscopically or over a guide wire might reduce the risk
of complications, especially oesophageal rupture.
Removable oesophageal stents
The SX-Ella Danis stent (ELLA-CS, Hradec Kralove, Czech
Republic) is a removable covered metal mesh stent placed endo-
scopically in the lower oesophagus without radiological screen-
ing. It has no role in the management of gastric variceal
bleeding. These stents can be left in situ for up to 2 weeks
unlike the Sengstaken–Blakemore tube which should be
removed after a maximum of 24–48 h.129 130 No published con-
trolled trials have compared this modality with balloon
tamponade.
Transjugular intrahepatic portosystemic stent-shunt
Several uncontrolled studies have examined the role of salvage
bare TIPSS in acute variceal bleeding. In a review of 15 studies,
control of bleeding was achieved in 90–100%, with rebleeding
in 6–16%.131 Mortality varied between 75% (in hospital) and
15% (30 day). It is important to appreciate that sclerotherapy
was used as ﬁrst-line endoscopic therapy in most of these
studies. Long-term follow-up of a study that compared TIPSS
with H-graft portacaval shunts in patients for whom non-
operative management had failed suggested that H-grafts were a
useful method of reducing portal pressure and had a signiﬁ-
cantly lower failure rate (p=0.04), but had no signiﬁcant
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improvement in overall survival despite a beneﬁt seen in Child’s
A and B disease.132 A recent RCT compared emergency porto-
caval surgery with bare TIPSS within 24 h of presenting with
acute oesophageal variceal bleeding in unselected cirrhotic
patients. Emergency portocaval surgery resulted in better out-
comes for long-term bleeding control, encephalopathy and sur-
vival (p<0.001).133 Before wider application of surgery for
acute variceal bleeding, more data are needed in light of the
recent adoption of covered stents.
There has also been a generalised established change in prac-
tice in using covered TIPSS stents (polytetraﬂuoroethylene
(PTFE)) rather than a bare metal stent, with evidence to support
this change. In randomised controlled studies, these stents were
shown to have higher primary patency rates than bare stents,
without signiﬁcant differences in survival, and the potential for
reduced incidence of hepatic encephalopathy.134 135
There is, however, growing evidence from two RCTs for the
earlier use of TIPSS in selected patients stratiﬁed by HVPG,
Child–Pugh class and active bleeding, and not just use as a
salvage option.6 136 Monescillo et al136 randomised patients
presenting with acute oesophageal variceal haemorrhage to bare
TIPSS or standard of care if the HVPG was ≥20 mm Hg within
24 h of admission. Signiﬁcantly reduced treatment failure, as
deﬁned by failure to control acute bleeding and/or early rebleed-
ing (12% vs 50%), was seen and improved survival (62% vs
35%) in the patients randomised to undergo a TIPSS procedure.
However, the standard of care was sclerotherapy and not com-
bination endoscopic and pharmacological treatment. This limita-
tion and the lack of availability of HVPG measurement in most
centres meant this trial did not have a signiﬁcant impact on clin-
ical practice.
Garcia-Pagan et al6 selected patients with active bleeding and
Child’s B cirrhosis or patients with Child’s C cirrhosis (Child’s
score <14) for randomisation to early PTFE-covered TIPSS
within 72 h or standard of care with VBL and pharmacological
treatment. This has shown encouraging results with reduced risk
of treatment failure (3% vs 50%), improved survival (86% vs
61% at 1 year), yet without increased risk of hepatic encephal-
opathy. The results were supported by an observational study
from the same group, although a survival beneﬁt was not
seen.137 Furthermore, a recent well-conducted observational
study did not demonstrate such high survival rates with early
TIPSS, with 11-year survival of 67%, which was similar to that
of patients given endoscopic and pharmacological treatments
only.138 Therefore, larger multicentred RCTs need to be under-
taken to further evaluate the role of early TIPSS. It is important
to make the distinction between salvage TIPSS and early TIPSS
to prevent rebleeding.
Liver transplantation
This is probably appropriate only for patients who bleed while
awaiting liver transplantation, although studies comparing VBL
or TIPSS placement with urgent liver transplantation in this
situation need to be done. Liver transplantation is an exceed-
ingly rare option for the vast majority of patients, both because
it is not commonly available and because of shortages and
delays in organ procurement. No controlled trials of liver trans-
plantation in uncontrolled/active bleeding are available.
Recommendations for the control of variceal bleeding in cir-
rhosis are given below and in ﬁgure 3.
Recommendations: control of active variceal haemorrhage in
cirrhosis (ﬁgure 3)
1. Suggestions for resuscitation and initial management
1.1. Units offering an emergency acute upper gastrointestinal
bleeding service should have expertise in VBL, balloon
tamponade and management of gastric variceal bleeding
(level 5, grade D).
1.2. Transfuse patients with massive bleeding with blood,
platelets and clotting factors in line with local protocols
for managing massive bleeding (level 5, grade D).
1.3. Base decisions on blood transfusion on the full clinical
picture, recognising that overtransfusion may be as dam-
aging as undertransfusion. A restrictive transfusion
policy aiming for a haemoglobin of 70–80 g/L is sug-
gested in haemodynamically stable patients (level 1b,
grade B).
1.4. Do not offer platelet transfusion to patients who are not
actively bleeding and are haemodynamically stable
(level 5, grade D).
1.5. Offer platelet transfusion to patients who are actively
bleeding and have a platelet count of <50×109/L
(level 5, grade D).
1.6. Offer fresh frozen plasma to patients who have either:
▸ a ﬁbrinogen level of <1 g/L (level 5, grade D), or
▸ a prothrombin time (international normalised ratio)
or activated partial thromboplastin time >1.5 times
normal (level 5, grade D).
1.7. Offer prothrombin complex concentrate to patients who
are taking warfarin and actively bleeding (level 5, grade D).
1.8. Treat patients who are taking warfarin and whose upper
gastrointestinal bleeding has stopped in line with local
warfarin protocols (level 5, grade D).
1.9. There is insufﬁcient evidence for the use of recombinant
factor VIIa in acute variceal haemorrhage (level 1b,
grade B).
2. Suggestions for timing of upper gastrointestinal endoscopy:
2.1. Offer endoscopy to unstable patients with severe acute
upper gastrointestinal bleeding immediately after resusci-
tation (level 5, grade A).
2.2. Offer endoscopy within 24 h of admission to all other
patients with upper gastrointestinal bleeding (level 2b,
grade A).
2.3. Units seeing more than 330 cases a year should offer
daily endoscopy lists. Units seeing fewer than 330 cases
a year should arrange their service according to local
circumstances (level 5, grade D).
3. Control of bleeding:
3.1. Antibiotics are recommended for all patients with suspected
or conﬁrmed variceal bleeding (level 1a, grade A).
3.2. In all patients, vasoconstrictors such as terlipressin or
somatostatin are recommended and should be started as
soon variceal bleeding is suspected and continued until
haemostasis is achieved or for up to 5 days. Octreotide
(unlicensed) is suggested if terlipressin or somatostatin
are unavailable (level 1a, grade A).
3.3. Variceal band ligation is recommended as the preferred
endoscopic method (level 1a, grade A).
3.4. After satisfactory haemostasis with the methods above,
and depending on local resources, early covered TIPSS
(<72 h after index variceal bleed) can be considered in
selected patients with Child’s B cirrhosis and active
bleeding or Child’s C cirrhosis with Child’s score <14
(level 1b, grade B).
3.5. Proton pump inhibitors are not recommended unless
otherwise required for peptic ulcer disease (level 1b,
grade B).
4. Failure to control active bleeding:
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4.1. If bleeding is difﬁcult to control, a Sengstaken–
Blakemore tube should be inserted until further endo-
scopic treatment, TIPSS or surgery is performed depend-
ing on local resources and expertise (level 1b, grade B).
4.2. Specialist help should be sought at this time and transfer
to a specialist centre should be considered. Units that do
not offer a TIPSS service should identify a specialist
centre which offers a 24 h emergency TIPSS service and
have appropriate arrangements for safe transfer of
patients in place (level 2a, grade B).
5. Areas requiring further study:
5.1. The efﬁcacy of restrictive blood transfusion in variceal
haemorrhage.
5.2. The role of blood products in variceal haemorrhage.
5.3. The utility of early TIPSS (<72 h) in acute variceal
haemorrhage.
5.4. The role of removable oesophageal stents in acute vari-
ceal haemorrhage.
5.5. The role of haemostatic powders in acute variceal
haemorrhage.
5.6. The role of proton pump inhibitors in variceal
haemorrhage.
6. Quality indicators:
6.1. Antibiotic administration in acute variceal bleeding
within 1 day either before or after the procedure (level
1a, grade A).
Numerator; patients with an acute variceal bleed who
have received antibiotics within 1 day either before or
after the procedure.
Denominator; patients with an acute variceal bleed.
6.2. Endoscopy performed within 24 h of presentation of an
acute variceal bleed (level 2b, grade A).
Numerator; patients with an acute variceal bleed who
have received endoscopy within 24 h of presentation.
Denominator; patients with an acute variceal bleed.
SECONDARY PROPHYLAXIS OF VARICEAL HAEMORRHAGE
β Blockers
A meta-analysis of 12 trials comparing propranolol or nadolol139
with no active treatment showed a signiﬁcant reduction in
rebleeding but no signiﬁcant reduction in mortality.140 The
greater reduction in portal pressure with carvedilol compared
with propranolol has been described in the section ‘Primary
prophylaxis’ of this guideline.
Nitrates
The addition of ISMN to NSBB has been shown to reduce vari-
ceal rebleeding compared with NSBB alone, although no sur-
vival beneﬁt was seen.141 In addition, adverse events leading to
drug withdrawal were more common in the group receiving
combined drug treatment. A meta-analysis of ISMN alone or
with either NSBB or endoscopic therapy reported that there was
no mortality beneﬁt from combining nitrates and NSBB com-
pared with NSBB alone.142
Side effects of ISMN include dizziness and headache. Owing
to the side effects and relative lack of data, ISMN is not com-
monly used in clinical practice.
A recent RCT of 121 patients reported carvedilol to be
similar to combined ISMN and NSBB therapy in the prevention
of variceal rebleeding and mortality, although severe adverse
events were less common with carvedilol.143
Simvastatin
A recent abstract of a multicentre RCT of 158 patients reported
a survival beneﬁt (91% vs 78%, p=0.03) from adding simvasta-
tin to VBL and NSBB compared with placebo, VBL and NSBB,
as treatment for the prevention of variceal rebleeding.144 There
was no difference in rebleeding and the survival beneﬁt was
restricted to Child A and B patients. Serious adverse events were
similar in both groups. More data are required to investigate
this interesting observation of a survival beneﬁt from simvastatin
in this situation, which may relate to its effects on hepatocellular
function, ﬁbrosis and portal pressure.
Proton pump inhibitors
A double-blind randomised placebo-controlled trial showed that
pantoprazole reduced the size of ulcers in patients who under-
went VBL. However, the total number of ulcers and other out-
comes were similar in the two groups.145
Endoscopic therapy
VBL has been accepted as the preferred endoscopic treatment
for the prevention of variceal rebleeding, with a lower rate of
rebleeding, mortality and complications than sclerother-
apy.146 147 The time interval between VBL sessions to achieve
eradication of varices is debateable. However, a recent RCT
comparing monthly with biweekly VBL after initial haemostasis
with VBL in 70 patients suggested that there were fewer
post-VBL ulcers in the monthly group (11% vs 57%;
p<0.001).148 Variceal recurrence, rebleeding and mortality were
similar in both groups.
Two meta-analyses showed there is no evidence that the add-
ition of sclerotherapy to VBL improves clinically relevant out-
comes, including variceal rebleeding and death, and the
combination led to higher stricture rates.149 150
Endoscopic therapy versus drug therapy
VBL has been reported to be more effective than combined
NSBB and ISMN drug therapy.151 However, an 8-year
follow-up study of this RCT found that although VBL was
superior in reducing variceal rebleeding, survival rates were sig-
niﬁcantly higher in the group treated with combined drug treat-
ment.152 Other studies have found no superiority of VBL over
combined drug therapy for prevention of variceal rebleeding or
mortality.153 154 A recent small multicentre RCT reported carve-
dilol to be similar to VBL in the prevention of variceal rebleed-
ing, with a trend in favour of survival with carvedilol (73% vs
48%, p=0.110).155
Several meta-analyses have compared drug therapy with VBL
in the prevention of variceal rebleeding. One meta-analysis of
six RCTs showed no signiﬁcant difference in variceal rebleeding
rates when comparing VBL alone with combined NSBB and
ISMN therapy. However, all-cause mortality was signiﬁcantly
higher in patients treated with the VBL (RR=1.25, 95% CI
1.01 to 1.55).156 Three meta-analyses comparing drug therapy
(NSBB alone or with ISMN) with endoscopic therapy alone
reported no difference in variceal rebleeding or mortality.157–159
Endoscopic+drug therapy versus either alone
Numerous studies and several meta-analyses have compared
combined endoscopic and drug therapy with monotherapy
(endoscopic or drugs alone) in the prevention of variceal
rebleeding. A meta-analysis of 23 trials assessing sclerotherapy
or VBL combined with NSBB reported that combination
therapy reduced rebleeding more than either endoscopic
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therapy or NSBB alone (pooled RR=0.68, 95% CI 0.52 to
0.89), although no difference in mortality was detected.160
A meta-analysis of fewer studies suggested no signiﬁcant dif-
ference in rebleeding between combined drug and VBL therapy
and either alone.157 A further meta-analysis reported reduced
variceal rebleeding (RR=0.601, 95% CI 0.440 to 0.820) but
similar mortality with combined drug and endoscopic therapy
versus endoscopic therapy alone.159 Another meta-analysis of
17 trials (14 using sclerotherapy and three using VBL) reported
that combined endoscopic and NSBB therapy reduced rebleed-
ing (OR=2.20, 95% CI 1.69 to 2.85) and overall mortality
(OR=1.43, 95% CI 1.03 to 1.98) compared with endoscopic
therapy alone.161
A further meta-analysis of 10 RCTs suggested that combin-
ation therapy reduces the risk of rebleeding from oesophageal
varices compared with VBL (RR=0.68, 95% CI 0.45 to 0.93)
or medical treatment (RR=0.60, 95% CI 0.43 to 0.84).162 This
meta-analysis included seven trials comparing combination
therapy with VBL and three trials comparing combination
therapy with drug treatment. Combined VBL and drug therapy
gave a survival beneﬁt when compared with VBL alone
(RR=0.52, 95% CI 0.27 to 0.99), but not when compared with
medical treatment alone.
Another recent meta-analysis assessed ﬁve studies comparing
VBL alone with combination VBL and drug therapy, and four
studies comparing drugs alone or combined with VBL.163 This
found that adding drugs to VBL reduced rebleeding (RR=0.44,
95% CI 0.28 to 0.69) with a trend towards reduced mortality,
but adding VBL to drug treatment did not signiﬁcantly affect
either rebleeding or mortality.
The meta-analyses are not entirely consistent, although it
would appear that combined VBL and drug treatment might
improve survival, but is likely to increase adverse effects com-
pared with VBL alone. There appears to be less clear beneﬁt
from combined VBL and drug treatment compared with drug
treatment alone.
Transjugular intrahepatic portosystemic stent-shunt
Three meta-analyses comparing TIPSS with endoscopic treat-
ment (sclerotherapy or VBL) have been published.164–166 The
results are similar, with the largest meta-analysis of 12 RCTs
showing that (bare) TIPSS reduces variceal rebleeding
(OR=0.32, 95% CI 0.24 to 0.43), but is associated with an
increased risk of encephalopathy (OR=2.21, 95% CI 1.61 to
3.03).166 No differences in survival were seen.164–166 Despite
the problem of shunt insufﬁciency and the cost of shunt surveil-
lance, TIPSS has been shown to be more cost-effective than
endoscopic therapy.167
A meta-analysis of six studies comparing TIPSS (both bare
and covered) with or without variceal embolisation showed that
adjuvant embolisation during TIPSS reduced rebleeding
(OR=2.02, 95% CI 1.29 to 3.17) with similar shunt dysfunc-
tion, encephalopathy and mortality rates.168 However, owing to
heterogeneity of the study methodology, the authors recom-
mended larger randomised studies using covered stents to
conﬁrm the ﬁndings. Generally, TIPSS placement using
PTFE-covered stents134 is recommended for patients for whom
endoscopic and pharmacological treatment for the prevention
of variceal rebleeding fails.1
The evidence for undertaking an ‘early’ TIPSS procedure6 in
patients shortly after a ﬁrst variceal bleed has been discussed in
the “Management of acute variceal bleeding” section of this
guideline.
Surgery
A meta-analysis demonstrated that non-selective shunts reduced
rebleeding compared with no active treatment or sclerotherapy,
at the expense of increased encephalopathy, with no survival
beneﬁt.68 Non-selective shunts resulted in similar outcomes
compared with distal splenorenal shunts.68 Extended follow-up
of a randomised study comparing portocaval shunt surgery with
sclerotherapy following acute variceal bleeding, reported better
long-term bleeding control (100% vs 20%, p<0.001) and
improved survival (5-year survival 71% vs 21%, p<0.001) in
the portocaval shunt arm.169 Distal splenorenal shunt surgery
was compared with TIPSS in a multicentre RCT including 140
patients with Child’s A and B cirrhosis.170 Results showed
similar rebleeding and survival, but higher rates of shunt dys-
function and re-intervention in the TIPSS group, although
covered stents were not used. A follow-up study suggested that
TIPSS was more cost-effective.171
Portosystemic shunts (total surgical, distal splenorenal or bare
TIPSS) were compared with endoscopic therapy for variceal
rebleeding in a Cochrane database systematic review.172
Twenty-two trials incorporating 1409 patients were included. All
shunt therapies reduced rebleeding (OR=0.24, 95% CI 0.18 to
0.30) at the expense of higher rates of encephalopathy
(OR=2.09, 95% CI 1.20 to 3.62), with no survival advantage.
TIPSS was complicated by a high incidence of shunt dysfunction.
Laparoscopic splenectomy plus VBL was also compared with
TIPSS for variceal rebleeding in a recent non-randomised trial
of 83 patients.173 This reported surgery plus VBL to be better
than TIPSS in preventing variceal rebleeding, with low rates of
encephalopathy.
Liver transplantation should be considered in eligible patients
following a variceal bleed determined by the selection criteria of
the country.174 There is no clear evidence that prior shunt
surgery has a signiﬁcant impact on transplant outcome.169
Recommendations for the secondary prophylaxis of variceal
bleeding in cirrhosis are given below and in ﬁgure 3.
Recommendations: secondary prophylaxis of variceal haemor-
rhage in cirrhosis (ﬁgure 3)
1. Should VBL be used in combination with NSBB?
1.1. NSBB (propranolol or nadolol)+VBL combination
therapy are recommended as secondary prophylaxis
(level 1a, grade A).
1.2. NSBB or VBL monotherapy are suggested as alternative
options taking into account patient preference and clin-
ical judgement (level 1a, grade B).
1.3. Carvedilol is suggested as an alternative to propranolol
and nadolol (level 1b, grade B).
1.4. If NSBB alone are used, there is no need to undertake
further endoscopy unless clinically indicated (level 1a,
grade A).
1.5. We recommend that VBL alone is used to eradicate
varices if there are contraindications or intolerance to
combined use with NSBB (level 1a, grade A).
2. What is the optimal protocol for VBL?
2.1. It is suggested that varices are banded at 2–4-weekly
intervals until eradication (level 1b, grade B).
2.2. After successful eradication of the varices, patients
should be endoscoped at 3 months, then 6 monthly
thereafter. Any recurrent varices should be treated with
further VBL until eradication (level 1b, grade B).
2.3. Proton pump inhibitors are not recommended unless
otherwise required for peptic disease (level 1b, grade B).
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3. When is TIPSS indicated?
3.1. We suggest that TIPSS is used for patients who rebleed
despite combined VBL and NSBB therapy (or when mono-
therapy with VBL or NSBB is used owing to intolerance or
contraindications to combination therapy), and in selected
cases owing to patient choice. PTFE-covered stents are
recommended (level 1a, grade A).
3.2. Where TIPSS is not feasible in Child’s A and B patients,
we suggest shunt surgery can be used where local
expertise and resources allow (level 1b, grade B).
4. Areas requiring further study:
4.1. Combination of VBL and carvedilol (or other NSBB)
versus carvedilol as monotherapy.
4.2. Comparison of carvedilol with propranolol in secondary
prophylaxis.
4.3. Optimum time interval between VBL sessions.
4.4. Strategy of VBL or NSBB discontinuation after variceal
eradication during combination therapy with VBL
+NSBB.
4.5. Strategy of VBL add-on therapy to failure of NSBB
monotherapy.
4.6. Strategy of NSBB add-on therapy to failure of VBL
monotherapy.
4.7. Role of early TIPSS in secondary prophylaxis.
4.8. Role of statins in secondary prophylaxis.
5. Quality indicator:
5.1. Institution of secondary prophylaxis after acute variceal
bleeding (level 1a, grade A)
Numerator; patients with an acute variceal bleed who
have received either NSBB or banding or both within
4 weeks of the index bleed.
Denominator; patients with an acute variceal bleed.
GASTRIC VARICES
Natural history
At ﬁrst endoscopy in patients with portal hypertension, 20% are
shown to have gastric varices.175 They are commonly seen in
patients with portal hypertension due to portal or splenic vein
obstruction.175 Only 10–20% of all variceal bleeding occurs
from gastric varices, but outcome is worse than with bleeding
from oesophageal varices.175 176
Gastric varices can be classiﬁed on the basis of their location
in the stomach and relationship with oesophageal varices. This
classiﬁcation has implications for management. The commonly
used Sarin classiﬁcation divides them into (a) gastro-oesophageal
varices (GOV), which are associated with oesophageal varices;
and (b) isolated gastric varices (IGV), which occur independ-
ently of oesophageal varices.175 Both GOV and IGV are subdi-
vided into two groups. Type 1 GOV are continuous with
oesophageal varices and extend for 2–5 cm below the gastro-
oesophageal junction along the lesser curvature of the stomach.
Type 2 GOV extend beyond the gastro-oesophageal junction
into the fundus of the stomach. Type 1 IGV refers to varices
that occur in the fundus of the stomach and type 2 IGV
describes varices anywhere else in the stomach, including the
body, antrum and pylorus. The most common type of varices
seen in cirrhosis is GOV type 1. Patients who bleed from IGV
are at a signiﬁcantly higher risk of dying from an episode of
variceal bleeding than patients bleeding from GOV.177
Management of acute gastric variceal bleeding
Although no studies have reported the use of vasopressors and
antibiotics speciﬁcally for the initial management of gastric vari-
ceal haemorrhage, any patient with suspected variceal bleeding
should be managed as described above (see section
‘Management of active variceal haemorrhage’). Once endoscopy
has identiﬁed the source of bleeding as gastric varices, thera-
peutic options include endoscopic methods, TIPSS, other radio-
logical procedures, surgery and long-term NSBB. Splenic vein
thrombosis should be considered and appropriate investigations
undertaken in patients presenting with gastric variceal bleeding.
Endoscopic therapy
Endoscopic sclerotherapy
Sclerotherapy has been largely replaced by VBL and tissue adhe-
sives or thrombin when appropriate for gastric varices, owing to
the lower complication and rebleeding rates.
Endoscopic VBL
Standard VBL or the use of detachable snares has been shown
to control active bleeding from gastric varices, but rebleeding
and recurrence rates are high.178 179 As GOV-1 are generally
considered extensions of oesophageal varices, VBL is often used
to treat bleeding from here. However, given the larger diameter
and the anatomy of other types of gastric varices, and the
limited data on use of VBL in this situation, this technique is
generally not recommended for these.
Endoscopic injection therapy with tissue adhesives
Numerous studies have reported the use of tissue adhesives,
most commonly histoacryl (N-butyl-cyanoacrylate), in the treat-
ment of gastric varices.180–194 Variations in technique, dilution
with lipiodol and follow-up strategy have been described. These
studies have reported an initial haemostasis success rate with
tissue glue of 86–100%, with rebleeding rates of 7–28%.
Uncommon, but severe complications, including emboli to the
pulmonary and cerebral circulations, have been described.181
A randomised study compared cyanoacrylate injection with
VBL in 60 patients with gastric variceal bleeding.186 Patients
treated with cyanoacrylate had a higher haemostasis rate (87%
vs 45%), lower rebleeding (31% vs 54%) and lower mortality
(29% vs 48%) than those treated with VBL. Another rando-
mised study comparing cyanoacrylate with VBL in 97 patients
with gastric variceal bleeding, reported equal haemostasis rates
at 93%, but signiﬁcantly higher rebleeding with VBL (72% vs
27%).193 This study reported no difference in survival or com-
plications between groups.
A non-randomised study comparing cyanoacrylate with VBL
for gastric variceal bleeding reported similar haemostasis rates,
but lower rebleeding with cyanoacrylate (32% vs 72%).194
Survival and complication rates were similar in both groups. In
a controlled but non-randomised study comparing cyanoacrylate
with sclerotherapy for gastric variceal bleeding, Oho et al188
showed that the haemostasis rate was signiﬁcantly higher in the
cyanoacrylate group. Survival was also signiﬁcantly greater in
patients treated with cyanoacrylate.
Mishra et al187 reported a randomised study comparing
cyanoacrylate injection with β blockers in the prevention of
rebleeding in 67 patients with bleeding GOV-2 or IGV-1.
During a median 26-month follow-up, patients in the cyano-
acrylate group had signiﬁcantly lower rates of both variceal
rebleeding (15% vs 55%) and mortality (3% vs 25%).
Treatment modality, presence of portal hypertensive gastropathy
and gastric variceal size >20 mm correlated with mortality.
Another recent RCT compared repeated gastric variceal obtura-
tion with or without NSBB in patients with bleeding GOV-2 or
IGV-1.182 Mortality and rebleeding rates were similar in the two
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groups, although adverse effects were more common in the
combination group.
In a non-randomised study, Lee et al185 suggested that endo-
scopic ultrasound (EUS)-guided biweekly cyanoacrylate injection
versus ‘on demand’ injection after recurrent bleeding led to sig-
niﬁcantly lower rebleeding (19% vs 45%) from gastric varices,
although survival was similar. However, others have not con-
ﬁrmed this approach.189 EUS-guided coil therapy has recently
been described as having similar efﬁcacy, but fewer adverse
events, compared with cyanoacrylate injection in a small non-
randomised study.191
Binmoeller et al180 described a new method for the manage-
ment of fundal gastric varices in 30 patients, using EUS and a
combination of 2-octyl-cyanoacrylate and coils. Haemostasis
was achieved in 100% of patients with no procedure-related
complications. Use of coils appeared to reduce the volume of
cyanoacrylate required to obliterate varices.
Endoscopic injection of thrombin
Injection of bovine thrombin to successfully control gastric vari-
ceal bleeding was initially described in a small cohort in
1994.195 Varices were eradicated in all patients after a mean of
two injections. Przemioslo et al196 reported 94% haemostasis
and 18% rebleeding in 52 patients with gastric variceal bleeding
treated with bovine thrombin. Ramesh et al197 also studied
bovine thrombin for bleeding gastric varices. They reported
92% haemostasis, with no rebleeding during follow-up. No
adverse events or technical problems were noted. More recent
studies have used human rather than bovine thrombin because
of safety concerns with the latter. McAvoy et al198 reported on
the largest series of patients treated with human thrombin injec-
tion for gastric or ectopic variceal bleeding. They reported 11%
rebleeding in the 33 patients who had gastric variceal haemor-
rhage, with no signiﬁcant adverse events. A recent series by
Smith et al199 reported a high rate of initial haemostasis in acute
bleeding. However, failure to control bleeding or rebleeding was
reported in >50%, suggesting that thrombin has a role in bridg-
ing to deﬁnitive treatment in acute bleeding. Where thrombin
was used as prophylaxis, rebleeding occurred in 20%. To date,
no randomised studies assessing thrombin injection for gastric
variceal bleeding have been reported.
New endoscopic therapies
Two recent reports have described the successful use of
Hemospray (Cook Medical, USA) in the management of active
gastric variceal bleeding refractory to cyanoacrylate injection
therapy.200 201 In the latter case this was used as a bridge to a
TIPSS procedure,201 but in the former case TIPSS was not
undertaken owing to pre-existing cardiomyopathy.200 No
rebleeding was reported in either case at a 30-day follow-up.
Further data on the use of haemostatic powders in gastric vari-
ceal bleeding are required.
Balloon tamponade
Insertion of a Sengstaken–Blakemore or Linton–Nachlas tube
may sometimes help to temporarily stabilise the patient with
severe gastric variceal bleeding, which is uncontrolled by stand-
ard endoscopic methods as described above.127 The Linton–
Nachlas tube has been reported to have greater efﬁcacy in
gastric varices haemorrhage in a controlled trial.128 However,
rebleeding is almost universal if another treatment modality is
not instituted.
Transjugular intrahepatic portosystemic stent-shunt
An initial TIPSS series using bare stents reported control of
active bleeding from gastric varices in almost all patients in
whom the shunt was performed successfully.202–206 Tripathi
et al43 described 272 patients who had a TIPSS procedure for
either gastric or oesophageal variceal bleeding. They reported
similar rebleeding rates after TIPSS for either gastric or
oesophageal varices. Initial PPG was lower in patients with
bleeding from gastric varices. In addition, mortality was lower
in those patients with initial PPG >12 mm Hg, who had TIPSS
for gastric compared with oesophageal variceal bleeding. Shunt
insufﬁciency and encephalopathy rates were similar in both
groups. The authors suggested aiming to reduce HVPG to
<7 mm Hg in gastric variceal bleeding.
Lo et al207 undertook a randomised trial in 72 patients com-
paring TIPSS with cyanoacrylate injection in the prevention of
gastric variceal rebleeding. Control of active bleeding had
been achieved with cyanoacrylate in all patients before random-
isation. They reported a signiﬁcantly lower rate of gastric vari-
ceal rebleeding with TIPSS (11% vs 38%), although overall
upper gastrointestinal rebleeding was similar in both groups.
Encephalopathy was more common in those patients treated
with TIPSS (26% vs 3%), but overall complications and survival
were similar in both groups.
A non-randomised study compared TIPSS with cyanoacrylate
injection for gastric variceal bleeding.208 No differences were found
in haemostasis, rebleeding or survival, but the group treated with
TIPSS had increased encephalopathy. Another comparative study
described lower rebleeding with TIPSS, but reduced in-patient
length of stay with cyanoacrylate, and similar mortality.209 This
study also reported cyanoacrylate to be more cost-effective.
Other radiological procedures
The use of balloon-occluded retrograde transvenous obliteration
(B-RTO) for the treatment of bleeding gastric varices was pio-
neered by the Japanese.184 210 This procedure involves insertion
of a balloon catheter into an outﬂow shunt (gastrorenal or
gastric-inferior vena caval) via the femoral or internal jugular
vein. Blood ﬂow is blocked by balloon inﬂation, then the veins
draining gastric varices are embolised with microcoils and a
sclerosant injected to obliterate the varices.
In a small randomised study, B-RTO was compared with
TIPSS in the management of 14 patients with active gastric vari-
ceal bleeding and gastrorenal shunts.211 Immediate haemostasis,
rebleeding and encephalopathy were similar in both groups. In a
non-randomised study of 27 high-risk patients, Hong et al212
compared B-RTO with cyanoacrylate injection in acute gastric
variceal bleeding. Active bleeding at baseline was more common
in the cyanoacrylate group. Haemostasis rates after B-RTO and
cyanoacrylate were similar at 77% and 100%. Rebleeding was
higher in the cyanoacrylate group (71% vs 15%), with compli-
cations and mortality similar in both groups. This rebleeding
rate after cyanoacrylate is much higher than ﬁgures reported
from other studies.
A large Korean retrospective study evaluated B-RTO for the
management of gastric variceal haemorrhage.213 Technical
success of B-RTO was 97% with procedure-related complica-
tions seen in 4% and rebleeding in 22%. Another retrospective
study of B-RTO for bleeding gastric varices described 95% tech-
nical success and 50% 5-year survival.214 Cho et al215 assessed
B-RTO in 49 patients who had gastric varices with spontaneous
gastro-systemic shunts. Procedural success rate was 84% but two
procedure-related deaths occurred. No variceal recurrence or
1698 Tripathi D, et al. Gut 2015;64:1680–1704. doi:10.1136/gutjnl-2015-309262
Guidelines
 o
n
 3 June 2019 by guest. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2015-309262 on 17 April 2015. Downloaded from 
rebleeding was noted. It has been reported that B-RTO can
increase PPG and may aggravate pre-existing oesophageal
varices and ascites.215 216 Although B-RTO appears to be an
effective alternative to TIPSS in patients with gastric variceal
bleeding who have appropriate shunts,217 it is rarely performed
outside Asian centres.218
Percutaneous transhepatic variceal embolisation with cyano-
acrylate and standard endoscopic cyanoacrylate injection have also
been compared in a non-randomised study of 77 patients.219 The
authors reported lower rebleeding with the percutaneous
approach, although mortality was similar in both groups.
Surgery
Surgery for portal hypertension should be performed by experi-
enced surgeons in lower-risk patients, ideally in specialist
units.220 Because of the increasing use of simpler endoscopic
and radiological procedures as described above, the need for
such an intervention has reduced dramatically, and is mainly
conﬁned to splenectomy or splenic artery embolisation in
patients with splenic vein thrombosis.221 222
Under-running of gastric varices has been shown to control
active bleeding but is followed by recurrence of bleeding in
50% of patients and is associated with a perioperative mortality
of >40%.223 Complete devascularisation of the cardia, stomach
and distal oesophagus for bleeding from gastric varices is asso-
ciated with good control of bleeding but is followed by rebleed-
ing in >40% of patients and early mortality in about 50%.224
The use of distal splenorenal shunting for bleeding from gastric
varices in patients with cirrhosis was reported in six patients
with Child class A or B cirrhosis.225 Although good control of
bleeding was attained, two patients died in the postoperative
period. Orloff et al169 reported that a portal-systemic shunt can
be an effective treatment for bleeding varices in patients with
portal vein thrombosis and preserved liver function.
Primary prophylaxis of gastric variceal bleeding
A randomised study of 89 patients compared β blockers, cyano-
acrylate injection and no active treatment in the primary preven-
tion of bleeding from larger (>10 mm) GOV-2 and IGV-1.226
Over a 26-month follow-up period, bleeding occurred in 38%,
10% and 53% of patients in the β blocker, cyanoacrylate and
no-treatment groups, respectively. The cyanoacrylate group had
signiﬁcantly lower bleeding rates than the other groups for
GOV-2, but not for IGV-1 patients. Mortality was lower in the
group treated with cyanoacrylate (7%) than in those given no
treatment (26%) but was similar to that in the β blocker group
(17%). However, this was a small, single-centre study with an
unusually high failure rate for NSBB. Many clinicians have sig-
niﬁcant concerns about the safety of cyanoacrylate injection in
the context of primary prophylaxis.
In a retrospective study, Kang et al suggested that cyanoacryl-
ate injection may be an effective prophylactic treatment for
higher-risk gastric varices.227
A retrospective study evaluated the clinical outcomes of
B-RTO for gastric varices, in which the procedure was per-
formed as a primary prophylactic treatment in 40 patients.228
The procedure was successful in 79% of patients, although pro-
cedural complications were reported in 9%. Survival at 1 and 5
years was 92% and 73%, respectively.
Recommendations: management of active haemorrhage from
gastric varices (ﬁgure 3)
1. What is the optimal management of bleeding gastro-
oesophageal varices?
1.1. GOV-1: treat as for oesophageal varices (level 2b,
grade B).
1.2. GOV-2 and IGV:
1.2.1. We recommend initial endoscopic therapy with
cyanoacrylate injection (level 1a, grade A).
1.2.2. Thrombin may also be considered (level 4, grade C).
1.3. TIPSS can be considered, depending on local resources
and clinical judgement (level 3a, grade B).
2. In control of bleeding fails:
2.1. Balloon tamponade is suggested for GOV, IGV-1 until
deﬁnitive treatment is undertaken (level 2b, grade B).
2.2. Salvage TIPSS is suggested as the ﬁrst-line deﬁnite treat-
ment, where feasible (level 3a, grade B).
2.3. B-RTO or surgical shunting can be considered if TIPSS
is not possible (eg, portal vein thrombosis present) and
depending on local resources (level 3a, grade B).
3. What are the therapeutic options for prevention of rebleed-
ing from gastric varices?
3.1. We recommend that patients with GOV-1 are entered
into a VBL surveillance programme (level 2b, grade B).
3.2. We recommend endoscopic surveillance with cyano-
acrylate injection as needed for GOV-2 and IGV (note
the optimum endoscopic follow-up strategy remains
unclear)(level 2b, grade B). Thrombin can also be con-
sidered (level 4, grade C).
3.3. NSBB can be considered in certain circumstances after
taking into account the patient’s preferences and clinical
judgement (level 1b, grade B).
3.4. We suggest TIPSS if patients rebleed despite cyanoacryl-
ate injection. TIPSS can also be considered in other
selected patients (eg, those with large or multiple gastric
varices) (level 1b, grade B).
3.5. Shunt surgery may be used in selected patients with
well-compensated cirrhosis and depending on local
resources (level 3c, grade B).
3.6. Splenectomy or splenic artery embolisation should be
considered in all patients where there is splenic vein
thrombosis or left-sided portal hypertension (level 4,
grade C).
4. Is there a role for primary prophylaxis of gastric variceal
bleeding?
4.1. NSBB (level 2a, grade B) can be considered in selected
high-risk patients with large GOV-2 after taking into
account the patient’s preferences and clinical judgement.
4.2. Cyanoacrylate injection is not recommended outside
clinical trials (level 2a, grade A).
5. Areas requiring further study:
5.1. Role of thrombin in gastric varices, comparing this with
tissue adhesives in both acute gastric variceal bleeding
and secondary prophylaxis.
5.2. Role of TIPSS in acute gastric variceal bleeding and sec-
ondary prophylaxis.
5.3. Role of haemostatic powders in controlling refractory
active gastric variceal bleeding.
5.4. Role of NSBB in the prevention of rebleeding from
gastric varices.
5.5. Role of B-RTO as monotherapy or in combination with
endoscopic injection of tissue adhesives in prevention of
bleeding from gastric varices.
5.6. Role of EUS-guided injection of tissue adhesives or
thrombin.
5.7. Primary prevention of gastric variceal bleeding with
tissues adhesives and NSBB.
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